Doc #116 — Pharmaceutical Rationing and Shelf-Life Extension

---

RECOMMENDED ACTIONS

Phase 1 — First 48 hours

1. Secure pharmaceutical wholesale warehouses under government direction (Doc #1, Category A). EBOS Group/ProPharma is the single point of contact for the majority of NZ’s wholesale stock. [Phase: 1 — IMMEDIATE]
2. Issue emergency dispensing restrictions to all pharmacies: 30-day maximum supply per prescription, no stockpile dispensing, restricted OTC sales of key analgesics and antibiotics. Medsafe has authority to issue these under emergency provisions. [Phase: 1 — IMMEDIATE]
3. Secure cold-chain infrastructure. Ensure backup power at all hospital pharmacy cold rooms and major pharmaceutical cold-storage facilities. [Phase: 1 — IMMEDIATE]

Phase 1 — First two weeks

4. Complete national pharmaceutical inventory. Aggregate wholesale, hospital, community pharmacy, veterinary, and aged-care stocks into a national database. [Phase: 1 — URGENT]
5. Establish National Pharmaceutical Triage Authority. PHARMAC convenes. Issue triage categories and rationing protocols. [Phase: 1 — URGENT]
6. Publish SLEP-based shelf-life extension list. National guidance to all pharmacies and hospitals: do not discard medications beyond labeled expiry. Provide evidence-based extension guidelines. [Phase: 1 — URGENT]
7. Begin insulin registry. Every vial of insulin in NZ tracked and centrally allocated. Type 1 patients registered. [Phase: 1 — URGENT]

Phase 1 — First three months

8. Implement dose optimisation and deprescribing programme. Clinical guidelines issued. GPs begin systematic medication reviews. Priority: Type 2 diabetes insulin-to-oral conversion, cardiovascular dose reduction, PPI deprescribing. [Phase: 1]
9. Integrate veterinary pharmaceutical stocks. Inventory complete. Expert review board assesses human usability. Dual-use drugs identified and allocated. [Phase: 1]
10. Establish stability testing programme at University of Otago, University of Auckland, or Medsafe laboratories. Prioritise high-value drugs with limited SLEP data. [Phase: 1]
11. Print and distribute pharmaceutical rationing guidance to all healthcare providers and community pharmacies. Include the shelf-life extension list, triage categories, and prescriber guidelines. [Phase: 1]
12. Patient communication programme. Public messaging about medication rationing — honest, clinical, empathetic. Individual patient communication through GPs and pharmacists for medication changes. (Doc #2, Doc #122) [Phase: 1]

Phase 1–2 — Months 3–12

13. Ongoing inventory management and consumption tracking. Monthly updates on stock levels, consumption rates, and projected depletion dates for all triage Category 1 drugs. [Phase: 1–2]
14. Regional stock redistribution. Transfer drugs from regions with surplus to regions approaching shortage. National database enables this. [Phase: 1–2]
15. Palliative care framework. For patients whose life-sustaining medications will be exhausted, establish early and honest communication, advance care planning, and expanded palliative care capacity. (Doc #122) [Phase: 1–2]
16. Coordinate with Doc #119 (Local Production). Triage Authority provides priority list for domestic production development based on projected stock-out timelines. [Phase: 1–2]

Phase 2–3 — Months 12+

17. Adjust rationing based on data. As actual consumption rates and shelf-life extension results become available, adjust triage protocols. Relax restrictions on drugs with confirmed deep stocks; tighten for drugs depleting faster than projected. [Phase: 2–3]
18. First domestic production outputs from Doc #119 programme begin supplementing rationed supply for selected drugs. [Phase: 2–3]
19. Transition from crisis rationing to managed scarcity. As supply stabilises for specific drug categories (either through confirmed long extension or domestic production), move those categories from strict rationing to controlled availability. [Phase: 2–3]

---

Economic Justification

Labour investment

A functional pharmaceutical rationing programme requires sustained staffing across multiple specialist roles. The following estimates are based on the programme scope described in this document:

Pharmacists — The core professional cadre. Community and hospital pharmacists are the primary implementers of dispensing restrictions, shelf-life extension protocols, dose optimisation, and patient communication. The NZ pharmacy workforce numbers approximately 4,000+ registered pharmacists.³ Under rationing, perhaps 20–30% of their working time — representing roughly 800–1,200 pharmacist-FTE — shifts from routine dispensing to active rationing management: inventory assessment, triage protocol implementation, therapeutic switching decisions, and patient counselling for medication changes. This is not a new deployment but a reallocation of existing professional capacity. The person-year cost is not additive to the economy — pharmacists are already employed — but the opportunity cost (reduced clinical dispensing throughput) is real and is addressed below.

Logistics coordinators — The national pharmaceutical inventory and redistribution system requires warehouse-level logistics management. At the EBOS/ProPharma distribution level, existing logistics staff can be redirected under government oversight. For regional redistribution (Section 7.3), an estimated 10–20 regional logistics coordinators would need to be assigned, drawn from existing health system operations or the transport sector. This represents approximately 10–20 person-years per year while the redistribution programme operates, declining as stocks in specific categories stabilise.

Data analysts — Ongoing inventory tracking and consumption monitoring (Action 13) requires analytical capacity to translate raw stock data into projected depletion timelines, flag categories approaching critical thresholds, and model the effect of dose optimisation programmes on supply duration. An estimated 5–10 data analyst-FTE during the first year, declining to 3–5 as the system matures. This is a specialist role; relevant skills exist within PHARMAC, Te Whatu Ora, and NZ’s university health informatics community.

Warehouse and inventory managers — At each major pharmaceutical storage location — EBOS/ProPharma warehouses in Auckland and Christchurch, major hospital pharmacies, regional distribution points — dedicated inventory management staffing is required beyond normal operations. Estimated at 2–4 additional FTE per major node, totalling approximately 20–40 person-years across the system in Year 1.

Total programme staffing estimate: Excluding the pharmacist reallocation (which is a reorientation, not a new hire), the rationing programme requires approximately 35–70 additional person-years of specialist staffing in Year 1, declining to 20–40 in subsequent years as protocols are established and some categories are derationed. This is a modest investment relative to the healthcare workforce NZ already maintains.

Managed rationing vs. uncontrolled consumption

The counterfactual is not “no rationing programme” in some neutral sense. It is uncontrolled consumption leading to earlier total exhaustion of all pharmaceutical categories simultaneously.

Without rationing controls imposed in the first days:

• Hoarding rapidly depletes pharmacy-level stocks. Within weeks, patients who fear supply interruption will obtain as much supply as they can, emptying community pharmacy shelves for patients who need medications urgently. This is documented in every pharmaceutical emergency — including the early weeks of COVID-19, when paracetamol and other basic medications disappeared from pharmacy shelves across NZ and Australia.⁴
• High-value stocks are consumed on low-value indications. Antibiotics prescribed for viral infections, opioids dispensed beyond clinical need, Category 4 medications continuing to be dispensed at full volume — each of these accelerates the depletion of stocks that should be reserved for higher-priority clinical needs.
• Cold-chain medications spoil rather than being redistributed. Insulin and biologics in locations where cold chain fails are lost. Without a national visibility system, there is no mechanism to identify these losses or compensate by drawing from other locations.

Estimate: In an uncontrolled consumption scenario, the effective pharmaceutical supply duration for the most-consumed medication categories is approximately 2–5 months — consistent with the raw pipeline stock plus household stocks from NZ’s 90-day dispensing cycle, accelerated by panic hoarding and cold-chain failures (see ⁵ for pipeline stock estimates; Section 9.2 for the full stock analysis). Under aggressive rationing using the protocols in this document (dispensing restrictions, dose optimisation, systematic deprescribing, therapeutic switching, age-weighted allocation, and redistribution), physical supply extends to roughly 5–14 months for most drug categories (Section 9.3). SLEP-based shelf-life extension (Section 4) ensures that tablets consumed within this window remain chemically effective — but it does not create additional supply. Total death counts over five years are broadly similar across scenarios (35,000–56,000 without rationing vs 30,000–53,000 with aggressive rationing), but the composition is fundamentally different: aggressive rationing with age-weighted insulin allocation can potentially bridge most of NZ’s ~5,000 Type 1 children to domestic production — though this depends on maintaining cold-chain integrity over the insulin’s 2.5–3.5 year usable shelf life and achieving domestic production by Year 3 (Section 9.4). Person-years of life saved under aggressive rationing are roughly 2–2.5x higher than under no rationing (Section 9.5).

Breakeven: every month of extended supply is clinically significant

The question of when the rationing programme’s cost is “worth it” has a straightforward answer: from the first week.

• Insulin: Every month of extended insulin supply for Type 1 diabetes patients is, without euphemism, a month of survival for approximately 20,000–25,000 NZers who will die within weeks of insulin exhaustion. No cost-benefit calculation is needed here.
• Anticonvulsants: Every month of extended supply for the approximately 50,000–65,000 NZers with epilepsy represents prevention of breakthrough seizures with associated injury, incapacity, and mortality risk.
• Antibiotics: Every week of extended antibiotic supply prevents deaths from bacterial infections that, without treatment, progress to sepsis. In a post-event environment with increased infection risk and reduced surgical capacity, antibiotic exhaustion would cause an accelerating toll.
• Cardiovascular medications: Every month of extended supply for the 500,000–700,000 NZers on antihypertensives represents prevention of strokes and heart attacks that would otherwise remove productive, experienced people from the recovery workforce.

The rationing programme’s staffing cost — perhaps 35–70 person-years in Year 1 — is trivial compared to these stakes. The breakeven calculation does not require elaborate modelling: preventing even a single preventable death from pharmaceutical exhaustion covers the entire annual staffing cost of the programme in human-capital terms. Preventing thousands covers it by orders of magnitude.

Opportunity cost

The principal opportunity cost of the rationing programme is the diversion of pharmacists from direct clinical care to rationing administration.

This is a real cost, and it should be acknowledged explicitly rather than minimised. A pharmacist spending time on inventory management, SLEP protocol implementation, and redistribution logistics is not simultaneously providing patient counselling, compounding, or clinical pharmacy support in hospital settings. In a healthcare system already under severe stress from the post-event environment, every clinical pharmacist hour is genuinely valuable.

The resolution is not that this cost is unimportant — it is that the alternative (no rationing programme) produces an even larger loss of clinical pharmacist capacity as the stock exhausts. Pharmacists operating in a system with no medications to dispense provide no pharmaceutical value at all. The diversion of pharmacist time to rationing administration in Year 1 buys the years of continued pharmaceutical care that provides the platform for those pharmacists to remain clinically useful.

Practically, the diversion should be structured to minimise clinical impact: - Inventory and logistics functions should be staffed primarily by pharmacy technicians and data analysts rather than pharmacists where the clinical judgement requirement is low - Pharmacist involvement should be concentrated in the high-judgement tasks: triage category decisions, SLEP extension assessments for specific drugs, therapeutic switching guidance, and patient communication for complex medication changes - Hospital clinical pharmacy services — the highest-value pharmacist deployment — should be protected from diversion to the greatest extent possible, with rationing administration staffed by redeployment from community pharmacy settings where clinical value per FTE is lower

---

1. NZ’S PHARMACEUTICAL SYSTEM

1.1 How medicines reach NZ patients

NZ’s pharmaceutical supply chain is a single pipeline from global manufacturers to patients, with virtually no domestic manufacturing of active pharmaceutical ingredients (APIs):

1. Global manufacturers (primarily in India, China, Europe, and the US) produce APIs and finished dose forms
2. Importation into NZ by pharmaceutical companies holding Medsafe marketing approvals
3. Wholesale distribution by two dominant distributors — ProPharma (a subsidiary of EBOS Group) and CDC Pharmaceuticals (also EBOS-owned since 2013) — which together handle the vast majority of NZ’s pharmaceutical wholesale volume⁶
4. Retail and institutional dispensing through approximately 1,000 community pharmacies, hospital pharmacies across NZ’s public hospital network, and aged residential care facilities⁷
5. PHARMAC — the Pharmaceutical Management Agency — determines which medicines are publicly funded and negotiates prices, controlling access to approximately 2,000 chemical entities in the national formulary⁸
6. Medsafe — NZ’s medicines regulatory authority, a business unit of the Ministry of Health — approves medicines for the NZ market and sets labelling requirements including expiry dates⁹

1.2 Import dependence

Fact: NZ imports essentially all of its pharmaceuticals. The total value of pharmaceutical imports was approximately NZ$2.5–3 billion per year in recent years, with government pharmaceutical expenditure through PHARMAC’s Combined Pharmaceutical Budget approximately NZ$1.2–1.4 billion per year.¹⁰¹¹

Fact: NZ has minimal pharmaceutical manufacturing. A small number of companies — including Douglas Pharmaceuticals (Auckland) and AFT Pharmaceuticals (Auckland) — manufacture some finished dose forms (primarily generics) in NZ, but they rely entirely on imported active pharmaceutical ingredients (APIs).¹² The dependency chain runs deep: APIs are predominantly produced in India and China from petrochemical or fermentation feedstocks, packaged into finished doses by contract manufacturers, and shipped to NZ importers. When ocean freight stops, NZ’s domestic formulators exhaust their raw material buffers — typically measured in weeks to a few months of production stock — and then halt regardless of their manufacturing equipment. No API synthesis capability exists in NZ for any commonly prescribed drug class; establishing it would require organic chemistry facilities, reagent supply chains, and trained pharmaceutical chemists that currently do not exist at useful scale (see Doc #119).

Implication: Every pill, vial, inhaler, and tube of cream currently in NZ is part of a finite, non-renewable stock. Total in-country stock across all supply chain layers represents roughly 3–5 months of normal consumption for most drug categories (Section 1.4). It is finite.

1.3 PHARMAC and the NZ formulary

PHARMAC is NZ’s unique institution for pharmaceutical management, and it gives NZ a structural advantage that few countries possess for this crisis.¹³

Why PHARMAC matters now:

• Centralised purchasing data. PHARMAC knows exactly what has been purchased, in what quantities, for the entire publicly funded medicine supply. This data is the starting point for a national pharmaceutical inventory.
• Therapeutic Group Managers. PHARMAC staff have deep expertise in therapeutic alternatives — which drugs can substitute for which, what the clinical trade-offs are, and where therapeutic switching is safe. This expertise is essential for the rationing framework.
• Existing precedent for allocation decisions. PHARMAC already makes allocation decisions: it decides which drugs are funded and which are not, using cost-effectiveness and health-need criteria. The public and the medical profession are accustomed to PHARMAC making hard choices about medicine access. This institutional acceptance is invaluable.
• Sole-supply and preferred-supplier arrangements. PHARMAC’s contracts often mean NZ holds stock of specific brands and formulations. Knowing exactly which products are in-country simplifies the inventory task.

Limitation: PHARMAC’s data covers publicly funded medicines. Private prescriptions, over-the-counter medicines, and veterinary pharmaceuticals are tracked separately or not at all. The national inventory must go beyond PHARMAC’s dataset.

1.4 In-country stock levels

Estimate: Total in-country pharmaceutical stock is distributed across multiple layers of the supply chain. For most commonly prescribed medications, the aggregate stock across all layers represents roughly 3–5 months of normal consumption:¹⁴

• EBOS Group/ProPharma wholesale warehouses in Auckland and Christchurch hold the majority of pipeline stock — estimated at 4–8 weeks of national consumption for most drugs¹⁵
• Hospital pharmacies in major centres (Auckland, Wellington, Christchurch, Hamilton, Dunedin) hold 0.5–1 week of supply for their formulary items
• Community pharmacies (~1,000 nationally) typically hold 1–2 weeks of supply for their high-turnover items
• Household stocks — NZ’s 90-day dispensing cycle for chronic medications means patients typically hold approximately 6 weeks of their prescribed medications at home. For the ~1.2 million adults on long-term medications,¹⁶ this represents a substantial stock layer — roughly equivalent to the entire wholesale pipeline
• Aged residential care facilities hold days to weeks of supply for their residents’ medications
• Veterinary stocks — approximately 0.5–1 week of dual-use antibiotics

Some drugs — particularly those with long procurement lead times or sole-supply arrangements — may have deeper buffers; others (especially biologics with short shelf lives or cold-chain requirements) may have much less. These stock levels are not publicly reported at aggregate level and must be confirmed through the immediate inventory process described in Section 7.

---

2. PHARMACEUTICAL TRIAGE FRAMEWORK

2.1 The rationale for triage

Not all medicines are equally important when supply is finite. Peacetime prescribing treats conditions across a vast spectrum — from life-threatening to mildly inconvenient. When every pill consumed is one that will never be replaced, allocation must be based on clinical priority.

This is not new to medicine. Triage is standard practice in emergency and disaster medicine. What is new is the timescale: this is not a triage lasting hours or days (mass casualty event) but years or a decade (permanent supply severance). The principles are the same; the implementation is different.

2.2 Triage categories

Category 1 — Life-sustaining: supply interruption causes death within days to weeks

Drug/class	NZ patient population (estimate)	Stock duration concern	Substitution potential
Insulin (all types)	~270,000–300,000 people with diagnosed diabetes; ~20,000–25,000 Type 1 who are absolutely insulin-dependent17	Critical — cold-chain dependent, limited extension	None for Type 1. Type 2 patients may be managed with oral agents and lifestyle modification (Section 3)
Immunosuppressants (transplant patients)	~3,000–4,000 active transplant recipients18	Months to 1–2 years of stock	Very limited. Withdrawal means graft rejection and likely death
Anticoagulants (warfarin, dabigatran, rivaroxaban)	~80,000–100,000 patients on anticoagulants19	Good extension potential for warfarin tablets (years)	Warfarin is the preferred option — simple molecule, tablets extend well. Requires INR monitoring
Anticonvulsants (epilepsy)	~50,000–65,000 people with epilepsy20	Good extension potential for most (sodium valproate, carbamazepine, lamotrigine tablets)	Some switching possible between agents. Abrupt withdrawal dangerous
Thyroid replacement (levothyroxine)	~200,000+ patients21	Excellent extension potential — very stable tablet	No substitute for the drug itself, but tablets last decades. Low concern if stocks are adequate
Corticosteroids (adrenal insufficiency patients)	~5,000–10,000 patients dependent	Good extension potential for tablets	Limited. Adrenal crisis without replacement is fatal

Category 2 — Essential: required for treating acute, life-threatening conditions

Drug/class	Primary use	Stock concern	Notes
Antibiotics (all classes)	Infection treatment	Moderate — most solid forms extend well; watch liquid formulations	Must be rationed strictly. Cannot waste on viral infections or prophylaxis of low-risk conditions
Analgesics (opioids)	Severe pain, surgical anaesthesia	Good extension potential for morphine, codeine tablets	Controlled substance — already rationed to some extent. Rationing framework must prevent diversion
Anaesthetics (local and general)	Surgery	Variable — lidocaine solutions less stable than solid forms. Ketamine relatively stable	Surgery continues; anaesthesia is non-negotiable
Epinephrine/adrenaline	Anaphylaxis, cardiac arrest	Moderate — degrades but retains partial potency beyond expiry22	Prioritise for emergency use. Auto-injectors less stable than ampoules
Antiarrhythmics	Acute cardiac arrhythmia	Good extension for amiodarone tablets
Bronchodilators (salbutamol)	Acute asthma	Inhalers have moderate extension potential (2–5 years). Metered-dose inhalers depend on propellant integrity	~500,000+ NZers with asthma23 — large affected population

Category 3 — Important: prevents significant morbidity or disability

Drug/class	Primary use	Notes
Antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, diuretics)	Blood pressure control	Excellent extension potential for most. Large NZ patient population (~500,000–700,000 on treatment)24. Dose reduction may be safe for many patients (Section 3)
Statins	Cholesterol, cardiovascular risk	Good extension. However, in a post-event environment with radically changed diet and increased physical activity, many patients’ cardiovascular risk profile changes. Deprescribing may be appropriate
Oral hypoglycaemics (metformin, gliclazide)	Type 2 diabetes	Good extension for metformin. Critical to extend supply — every Type 2 patient managed on oral agents is one patient not needing insulin
Psychiatric medications (antidepressants, antipsychotics, anxiolytics, mood stabilisers)	Mental health conditions	Moderate–good extension. Abrupt withdrawal is dangerous for many psychiatric medications. Must be tapered, not stopped. See Doc #122 for mental health context
Contraceptives (oral, injectable, IUDs)	Family planning	Oral contraceptive pills extend well. IUDs already in situ last 5–10 years. Injectable depot formulations have moderate extension. Demographic implications of contraceptive failure are significant
Anti-inflammatory drugs (NSAIDs)	Pain, inflammation	Excellent extension for ibuprofen, naproxen, diclofenac tablets
Proton pump inhibitors (omeprazole, pantoprazole)	Gastric acid suppression	Good extension. Many patients can be dose-reduced or withdrawn

Category 4 — Deferrable: quality-of-life medications with limited survival impact

Drug/class	Rationale for deferral
Cosmetic treatments	No survival relevance
Erectile dysfunction medications	No survival relevance
Some allergy medications (antihistamines for mild allergies)	Uncomfortable but not dangerous to stop
Lifestyle supplements and vitamins (most)	Dietary management preferred — see Doc #3, Section 8
Sleep medications (most)	Non-pharmacological approaches should be first line
Topical treatments for minor skin conditions	Uncomfortable but not dangerous

2.3 Who decides

Institutional framework:

1. National Pharmaceutical Triage Authority: Established within the first two weeks, drawing on PHARMAC clinical staff, Medsafe regulatory expertise, and senior hospital pharmacists and physicians from major DHBs (or their successor health entities). This body sets the national triage categories and rationing rules.

2. Regional implementation: District health authorities (or Te Whatu Ora / Health New Zealand regional structures) implement triage decisions within their regions, adapting to local stock levels and patient populations.

3. Individual clinical decisions: Prescribers (doctors, nurse practitioners) make individual patient-level decisions within the triage framework. A doctor who believes a patient’s clinical need warrants a higher-category allocation can escalate through the regional health authority.

4. Appeals process: Patients who disagree with a triage decision can appeal to the regional health authority. The process must be transparent and timely — within days, not weeks. A functioning appeals process is a structural requirement for public acceptance of rationing (see Doc #3, Section 9 on procedural justice).

---

3. DOSE OPTIMISATION AND DEPRESCRIBING

3.1 The case for dose reduction

Many NZers are prescribed medications at doses that reflect peacetime clinical guidelines optimised for marginal benefit in a context of abundant supply. When supply is finite, the calculus changes. A 50% dose reduction that preserves 80% of the therapeutic benefit doubles the duration of the national stock of that drug.

This is not substandard care. It is evidence-based reallocation of a finite resource. In many cases, dose reduction is clinically appropriate independent of supply constraints:

• Antihypertensives: Many patients are on combination therapy at full doses. Reducing to lower doses of a single agent often provides adequate blood pressure control, particularly when combined with dietary changes (reduced salt, increased physical activity) that the post-event lifestyle may naturally produce.²⁵
• Statins: The cardiovascular risk reduction from statins follows a dose-response curve with diminishing returns. Half the standard dose provides roughly 80% of the LDL reduction.²⁶ In a post-event environment where diet shifts dramatically (less processed food, more vegetables, more physical activity), baseline cardiovascular risk may decrease for many patients.
• Proton pump inhibitors (PPIs): Widely overprescribed at full dose for long durations. Many patients can be stepped down to half-dose, alternate-day dosing, or withdrawn entirely with lifestyle management.²⁷
• Benzodiazepines and sleep medications: Many patients have been on these longer than clinically indicated. Supervised tapering frees significant stock while often improving patient outcomes.²⁸

3.2 Conditions where dose reduction is NOT safe

• Anticonvulsants: Dose reduction risks breakthrough seizures. Do not reduce without specialist guidance.
• Immunosuppressants (transplant): Dose reduction risks graft rejection. Do not reduce.
• Insulin (Type 1 diabetes): Dose reduction risks diabetic ketoacidosis. Dose titration should follow blood glucose, not supply rationing.
• Anticoagulants: Sub-therapeutic dosing risks thromboembolism. Must be monitored (INR for warfarin).
• Psychiatric medications (acute phase): Dose reduction during acute psychiatric illness risks relapse. Tapering should be managed, not imposed.

3.3 Deprescribing as a supply strategy

“Deprescribing” — the planned, supervised discontinuation of medications that are no longer necessary or where harms outweigh benefits — is an established clinical practice in peacetime.²⁹ Under rationing, it becomes a supply strategy:

• Polypharmacy review: Many elderly patients are on 5–10+ medications. Systematic review often identifies medications that can be safely stopped. NZ’s median age of ~38 years and growing elderly population means significant polypharmacy exists.³⁰
• Therapeutic duplication: Some patients take two drugs from the same class. Rationalise to one.
• Indication review: Some patients continue medications long after the original indication has resolved.

Estimate: Aggressive but clinically appropriate deprescribing across NZ’s population could reduce total pharmaceutical consumption by 10–25%. This is speculative but directionally supported by peacetime deprescribing research.³¹

AI-assisted clinical decision support. If the AI inference facility described in Doc #129 is operational, it can serve as a significant force multiplier for clinical staff working outside their specialty — which, under rationing conditions, will be most of them. GPs making deprescribing decisions for complex polypharmacy patients, nurses adapting protocols for substitute drugs, pharmacists assessing whether a therapeutic switch is safe for a specific patient — these are judgment-intensive tasks where access to specialist reasoning matters. The facility’s hub and community-level spoke devices (Doc #129) can support triage decisions, help clinicians evaluate drug interaction risks when switching medications, provide diagnostic assistance for unfamiliar presentations, and guide deprescribing assessments with patient-specific context. This is not a replacement for clinical expertise — a GP with twenty years of experience and a functioning AI system is more capable than either alone — but when the alternative is a generalist making specialist-level decisions with no support at all, inference-based guidance materially reduces error rates and improves allocation decisions.

3.4 The diabetes challenge

Diabetes is the single most difficult pharmaceutical rationing problem NZ faces. The numbers:

• Approximately 270,000–300,000 NZers have diagnosed diabetes (roughly 5–6% of the population), with a significant proportion of undiagnosed cases adding to the total³²
• Approximately 20,000–25,000 have Type 1 diabetes, requiring exogenous insulin for survival³³
• Approximately 250,000+ have Type 2 diabetes, of whom roughly 40,000–60,000 use insulin and the remainder are managed with oral agents and/or lifestyle modification³⁴
• Maori and Pacific populations have substantially higher diabetes prevalence — roughly 2–3 times the NZ European rate — creating an equity dimension to insulin rationing³⁵

Strategy for Type 2 diabetes:

The post-event environment may improve the metabolic situation for some Type 2 diabetes patients: caloric intake is likely to decrease (rationing), physical activity to increase (manual labour replaces sedentary work), processed food and refined sugar to disappear from the diet, and body weight to fall. For a proportion of patients currently on oral hypoglycaemics or insulin for Type 2 diabetes, these changes may reduce medication requirements significantly.³⁶

Performance gap: This is not a reliable substitution. The DiRECT trial (Lean et al., 2018) achieved Type 2 remission in approximately 46% of participants under structured intensive weight-loss conditions — meaning more than half did not achieve remission even under optimal managed conditions. Under post-event conditions, results will vary by individual metabolic profile, baseline HbA1c, duration of disease, and the degree of caloric restriction actually achieved. Patients with long-standing Type 2 diabetes and significant beta-cell loss are unlikely to achieve remission through lifestyle changes alone. Expectations should be calibrated: lifestyle modification is a meaningful demand-reduction strategy, not a reliable replacement for pharmacological management.

Action: Immediately begin supervised dose reduction trials for Type 2 diabetes patients, starting with those on insulin (converting to oral agents where possible) and those on multiple oral agents (simplifying to monotherapy with metformin where possible). Monitor blood glucose responses closely — do not assume lifestyle changes will achieve glycaemic control without ongoing clinical assessment. Every Type 2 patient who can be safely managed without insulin frees insulin for a Type 1 patient who requires it.

Strategy for Type 1 diabetes:

There is no substitute for insulin in Type 1 diabetes. The supply constraint is absolute. NZ’s total in-country insulin stock — across wholesale warehouses, hospital pharmacies, community pharmacies, and household supplies — is estimated at roughly 3–5 months of total insulin consumption (Section 9.2). Under aggressive rationing, with 50–60% of Type 2 insulin users successfully converted to oral agents and lifestyle management, total insulin consumption drops by roughly 40%, extending supply to an estimated 5–10 months. This is the working planning assumption for Type 1 supply — but it is highly uncertain. PHARMAC procurement data is the only reliable source, and until the national inventory is complete, insulin supply duration cannot be stated with confidence. It must be verified through immediate inventory and treated as the single highest-priority unknown. Domestic production of crude animal insulin (Doc #119, Year 3–5) or resumed trade are the only paths beyond exhaustion of existing stocks — and a gap of years separates even the most optimistic stock extension from the earliest plausible production date.

Actions:

• Absolute priority cold-chain management for insulin stocks
• National insulin registry: every vial tracked, allocated through a centralised system
• Dose optimisation: intensive blood glucose monitoring to minimise insulin use while maintaining safe control. This requires test strips, which are also finite — but less so than insulin
• Dietary management: very-low-carbohydrate diets reduce insulin requirements substantially for many patients³⁷
• Concentrate specialist diabetes care into regional centres to ensure optimal management

---

4. THE SLEP EVIDENCE

[Phase 1–3: Shelf-life extension protocols are applied from Day 1 and remain relevant throughout the years of managed scarcity. Stability testing (Section 4.4) is a Phase 1–2 activity as laboratory capacity exists.]

4.1 What SLEP is

The Shelf Life Extension Program is a joint programme of the US Department of Defense (DoD) and the FDA, established in 1986 to reduce the cost of replacing expired medications in military stockpiles.³⁸ The programme tests actual stored lots of medications using laboratory stability analysis — potency testing, dissolution testing, and degradation product analysis — to determine whether medications remain safe and effective beyond their labeled expiry dates.

This is not guesswork. SLEP involves actual chemical analysis of real stored medications. When SLEP extends a drug’s shelf life, it is because laboratory testing has confirmed that the drug in question still meets its original specifications.

4.2 Key findings

The landmark SLEP publication — Lyon et al. (2006) in the Journal of Pharmaceutical Sciences — reported results for 122 drugs (3,005 lots) tested between 1986 and 2005:³⁹

• 88% of lots tested were extended beyond their original expiry date
• Average extension: 5.5 years beyond labeled expiry
• Maximum extensions exceeded 15 years for some formulations
• Most common extensions: 1–10 years depending on drug and formulation

Subsequent SLEP data and independent research have broadly confirmed these findings:⁴⁰⁴¹

Drug category	Typical SLEP extension	Storage sensitivity	Notes
Solid oral doses (tablets, capsules) — most categories	5–15+ years beyond labeled expiry	Moderate — cool, dry, dark	The strongest evidence base. Many common drugs fall here
Ciprofloxacin (fluoroquinolone antibiotic)	10+ years in some lots	Low–moderate	One of the best-documented long-lived drugs42
Amoxicillin (penicillin antibiotic)	2–5 years typical	Moderate	Capsules and tablets stable; suspensions are not
Acetaminophen/paracetamol	5–10+ years	Low	Very stable in solid dose form
Ibuprofen	5–10+ years	Low	Very stable
Metformin (diabetes, oral)	5–10+ years	Low–moderate	Good news for Type 2 diabetes management
Amlodipine (antihypertensive)	5–10+ years	Low–moderate
Atenolol (beta-blocker)	5–10+ years	Low–moderate
Warfarin	3–7 years	Moderate	Requires potency monitoring
Prednisone/prednisolone	5+ years	Low–moderate
Hydrochlorothiazide	5–10+ years	Low
SSRIs (fluoxetine, sertraline)	3–7 years (limited data)	Moderate	Less SLEP data than older drugs; stability likely but less certain

4.3 What does NOT extend well

This is equally important. Some medications deteriorate in ways that reduce efficacy or create safety risks:

Tetracycline antibiotics (doxycycline, tetracycline): Degradation products of tetracycline-class antibiotics have historically been associated with a toxic syndrome (Fanconi syndrome). While modern formulations may be safer than the formulations that caused the original 1960s case reports, the precautionary position is to treat tetracyclines as having limited shelf-life extension potential.⁴³ This is a conservative estimate — some recent evidence suggests modern doxycycline formulations may be more stable than feared, but the risk profile warrants caution.

Insulin: All forms of insulin are proteins that degrade over time, accelerated by temperature. Unopened insulin vials stored at 2–8°C (standard refrigeration) have labeled shelf lives of 2–3 years. SLEP data on insulin extension is limited, and real-world extension beyond labeled expiry is unlikely to exceed 6–12 months even under ideal cold storage. Once the cold chain is compromised, insulin degrades within weeks to months.⁴⁴ This is the single hardest pharmaceutical constraint NZ faces.

Nitroglycerin: Volatile, sublimes out of tablets. Very limited shelf-life extension potential. Patients with angina who depend on sublingual nitroglycerin face an early supply constraint.⁴⁵

Liquid formulations (suspensions, solutions, syrups): Generally less stable than solid dose forms. Suspensions can settle irreversibly, solutions can degrade through hydrolysis, and preservative systems can fail. Extension potential is typically 1–3 years, less than solid forms.⁴⁶

Biologics (monoclonal antibodies, vaccines, blood products): Protein-based drugs that require cold-chain storage and have limited stability. Extension beyond labeled expiry is generally 6–18 months under ideal conditions and very limited if cold chain is compromised.⁴⁷

Epinephrine (adrenaline) auto-injectors (EpiPens): Epinephrine degrades over time, with potency declining after expiry. However, research shows that even expired EpiPens retain substantial potency — Cantrell et al. (2017) found that auto-injectors up to 4 years past expiry retained 80%+ of labeled epinephrine content.⁴⁸ In a survival context, a partially degraded EpiPen is far better than no epinephrine at all.

Ophthalmic preparations: Eye drops are sterile products in aqueous solution. Sterility and stability are concerns beyond expiry. Extension potential is limited.

4.4 Beyond SLEP: independent evidence

SLEP is the largest body of evidence, but independent research supports its conclusions:

• Cantrell et al. (2012): Analysed 8 medications found in a retail pharmacy, stored at ambient conditions, 28–40 years past their expiry dates. Twelve of 14 active ingredients tested were present at greater than 90% of labeled content. Notably, aspirin, codeine, and phenobarbital were all within acceptable potency limits decades after expiry.⁴⁹
• Cohen et al. (2000): 96 different medications stored in US military conditions; results broadly consistent with SLEP findings.⁵⁰
• Manufacturers’ expiry dates are conservative. Pharmaceutical companies have strong legal and financial incentives to set short expiry dates: it avoids liability risk and drives replacement purchases. The gap between labeled expiry and actual degradation is a feature of regulatory and commercial incentives, not of drug chemistry.⁵¹

4.5 What this means for NZ

What SLEP does: SLEP evidence confirms that most solid-dose medications remain chemically effective for 5–15 years beyond their labeled expiry date, under reasonable storage conditions. This means:

• Drugs that are near or past their labeled expiry at the time of the event should not be discarded — they are almost certainly still effective
• Tablets consumed months or years after the event will retain their potency
• The labeled expiry date is not a constraint on when medications can be safely used

What SLEP does not do: SLEP does not create more pills. If NZ holds 3–5 months of physical supply for a drug category (Section 9.2), that supply is consumed in months regardless of whether the tablets remain chemically stable for decades. SLEP ensures that every tablet consumed during the rationing period is fully effective — a tablet dispensed in Month 8 is just as potent as one dispensed in Month 1 — but it does not extend the number of months the physical stock lasts.

Where the distinction matters most: For the small number of drug categories where physical volume is large relative to consumption (levothyroxine — tiny dose, stable tablet, relatively small patient load per unit of wholesale stock) or where extreme dose-stretching is clinically meaningful (phenobarbital — decades of stability, gradual dose titration possible), SLEP combined with rationing may genuinely extend functional supply to years. For the majority of commonly prescribed drugs — cardiovascular medications, antibiotics, psychiatric medications, insulin — the physical stock represents months of consumption, and SLEP does not change this arithmetic. Section 9 provides the full gap analysis.

---

5. STORAGE OPTIMISATION

[Phase 1–3: Storage protocols must be established within weeks of the event and maintained continuously. Infrastructure upgrades (backup power, consolidation) are Phase 1 priorities.]

5.1 The physics of drug degradation

Most drug degradation follows Arrhenius kinetics: the rate of chemical degradation roughly doubles for every 10°C increase in temperature.⁵² This means storage temperature is the single most important variable in shelf-life extension.

Other degradation factors:

• Humidity: Accelerates hydrolysis and promotes microbial growth. Solid dose forms in blister packs are somewhat protected; those in open bottles are more vulnerable.
• Light: UV radiation degrades many drugs, particularly those in clear or translucent packaging.
• Oxygen: Oxidation degrades some drugs (particularly those with unsaturated bonds).

5.2 Optimal storage protocol for NZ conditions

Target conditions: 15–20°C, below 60% relative humidity, dark, in original sealed packaging where possible.

NZ’s temperate climate is an advantage. Average ambient temperatures in most of NZ are already in the 10–20°C range for most of the year.⁵³ Nuclear winter temperature reductions relevant to NZ’s latitude are uncertain and scenario-dependent; published modelling suggests Southern Hemisphere mid-latitude cooling in the range of 2–10°C in the first 1–3 years following a large nuclear exchange, with significant uncertainty bounds.⁵⁴ Even at the lower end of this range, cooler ambient temperatures improve passive pharmaceutical storage conditions for most medications. The practical implication: if climate control systems in warehouses fail, NZ’s post-event ambient temperatures may still fall within or near acceptable storage ranges for solid-dose drugs — though this should not be relied upon as a substitute for maintaining active climate control where possible.

Practical implementation:

1. Centralise wholesale stocks in optimal storage. EBOS/ProPharma warehouses are already climate-controlled. Maintain these facilities. If climate control systems fail, NZ’s post-event ambient temperatures (cooled by nuclear winter) still provide acceptable storage conditions for most drugs.

2. Hospital and pharmacy stocks: improve where possible. Ensure storage areas are cool, dry, and dark. Move medications away from exterior walls (temperature fluctuation), windows (light), and kitchens or bathrooms (humidity). This is low-cost, high-value.

3. Cold-chain medications: prioritise refrigeration. Insulin, biologics, some vaccines, and certain other medications require 2–8°C storage. These must have priority access to refrigeration, including backup power (Doc #65). Hospital pharmacy refrigerators and dedicated pharmaceutical cool rooms should be on backup generator circuits.

4. Packaging integrity. Drugs in sealed blister packs or foil-wrapped packaging last longer than those in opened bottles. Where possible, defer opening multi-dose containers until needed. When dispensing, dispense smaller quantities more frequently rather than large supplies that sit in patients’ homes under variable conditions.

5. Desiccants. Silica gel packets in storage containers reduce humidity exposure. NZ has silica gel in commercial supply (warehouse and shipping industry). Centralise and allocate to pharmaceutical storage.

5.3 NZ-specific storage locations

Optimal sites for pharmaceutical stockpile storage:

• South Island: Cooler ambient temperatures, particularly Central Otago and the Southern Lakes region. Average temperatures 2–5°C lower than Auckland. Under nuclear winter, South Island conditions would be well within ideal pharmaceutical storage range.
• Underground or semi-underground facilities: Constant temperature, reduced UV, reduced humidity fluctuation. Wine caves, cold stores, and below-grade commercial storage throughout NZ could be repurposed.
• Existing pharmaceutical warehouses: The ProPharma/EBOS warehouse infrastructure in Auckland and Christchurch is purpose-built for pharmaceutical storage. These facilities should be maintained and secured as national strategic assets (Doc #1, Category A).

5.4 Cold-chain management for biologics

The medications that require cold-chain storage are also the ones with the shortest effective shelf lives and the least extension potential. This is a compounding constraint: the drugs that are hardest to replace are also the most storage-demanding.

NZ’s cold-chain capacity:

• Hospital pharmacy refrigerators and freezers (every hospital has them)
• Community pharmacy refrigerators (every pharmacy has one or more)
• Commercial cold storage facilities (primarily in Auckland, Christchurch, and regional centres)
• Household refrigerators (~1.8 million households, each with at least one refrigerator)

Under the baseline scenario (grid at 85%+ from renewables, Doc #65), cold-chain refrigeration continues to function. The risk is localised or temporary power interruption, which could destroy temperature-sensitive stocks.

Mitigation:

• Backup generators at all pharmaceutical cold-storage locations (hospital pharmacies, major warehouse cold rooms)
• Temperature monitoring with alerts — if cold chain is broken, use affected insulin/biologics first (they remain usable for limited periods at room temperature)
• Consolidate cold-chain stocks into fewer, better-protected locations rather than dispersing them across many small refrigerators
• Prioritise insulin and critical biologics for the most reliable cold-storage facilities

---

6. VETERINARY PHARMACEUTICAL INTEGRATION

[Phase 1: Inventory and integration must occur in the first weeks. Ongoing veterinary-human stock balancing is a Phase 1–2 management task.]

6.1 The overlooked stockpile

NZ’s agricultural economy supports a substantial veterinary pharmaceutical supply chain that is rarely considered in human health emergency planning. Many veterinary drugs are chemically identical to human formulations — the same active ingredients, manufactured to the same standards, differing only in labelling and dose forms.⁵⁵

NZ’s veterinary pharmaceutical stock includes:

• Antibiotics: penicillin, amoxicillin, tetracyclines, trimethoprim-sulfa, enrofloxacin (fluoroquinolone)
• Anti-inflammatories: meloxicam, flunixin, phenylbutazone
• Anaesthetics: ketamine, lidocaine, xylazine
• Antiparasitics: ivermectin, fenbendazole, praziquantel
• Nutritional supplements and electrolytes

Major NZ veterinary distributors: Provet NZ (veterinary division of EBOS Group) and NZ Veterinary Pathology supply the approximately 600+ veterinary practices across NZ.⁵⁶

6.2 Integration protocol

1. Inventory all veterinary pharmaceutical stocks alongside human pharmaceutical stocks — same urgency, same process
2. Identify human-usable drugs in veterinary stock. A pharmacist and veterinarian review board identifies which veterinary products are safe for human use, at what doses, and with what precautions
3. SLEP protocols apply equally. Shelf-life extension evidence is chemistry-based, not use-based. An amoxicillin tablet is an amoxicillin tablet whether labeled for dogs or humans
4. Maintain essential veterinary supply. NZ’s food production depends on animal health (Doc #74). Stripping veterinary stocks for human use while livestock epidemics go untreated would be counterproductive. Balance is required.
5. Antiparasitic drugs (ivermectin, fenbendazole) have dual use: livestock parasite management and potential human antiparasitic treatment. NZ’s farm supply stores (PGG Wrightson, Farmlands) hold significant stocks

6.3 Ethical and safety considerations

Using veterinary-labeled medications in humans raises safety concerns that must be managed:

• Dose forms may differ: Veterinary products may come in concentrations, flavours, or delivery systems unsuitable for humans. A veterinary injectable may be safe for human use; a veterinary drench formulated as a cattle pour-on may not.
• Excipients may differ: The active ingredient may be the same, but inactive ingredients in veterinary formulations may not be approved for human use. Risk assessment is needed per product.
• Public acceptance: People may resist taking “animal medicine.” Public communication must explain the scientific reality: the molecules are the same. Labelling is a regulatory distinction, not a chemical one.

---

7. IMPLEMENTATION

7.1 Immediate actions (Days 1–14)

Day 1–3: Secure wholesale stocks

Per Doc #1, pharmaceutical wholesale warehouses are Category A (wholesale requisition). Within 48 hours:

• Government contacts EBOS Group/ProPharma and directs that no further uncontrolled distribution occurs
• Existing warehouse staff continue operations under government oversight
• A pharmacist or pharmaceutical logistics specialist is embedded at each major warehouse
• Physical security provided if necessary (this is unlikely to be contentious — these are business warehouses, not homes)

Day 1–7: Pharmacy and hospital rationing rules

• Medsafe/PHARMAC issue emergency rationing guidelines to all community pharmacies and hospital pharmacies
• Immediate rules: (a) No more than 30-day supplies dispensed per prescription; (b) No repeat dispensing without clinical review; (c) Category 4 medications deprioritised; (d) Over-the-counter sales restricted for key categories (paracetamol, ibuprofen, antihistamines — to prevent hoarding)
• Controlled drugs (opioids, benzodiazepines) already have restricted supply infrastructure. Maintain and tighten.

Day 3–14: National pharmaceutical inventory

This is the critical enabling task. NZ must know what it has:

• Wholesale: EBOS/ProPharma inventory systems provide detailed data on warehouse stocks. This is the easiest and most valuable data source.
• Hospital pharmacies: Each hospital pharmacy has inventory management systems. Aggregate into a national database.
• Community pharmacies: More dispersed and varied. Pharmacy chains (Green Cross Health / Unichem, with approximately 280+ pharmacies, and Chemist Warehouse, expanding in NZ) have centralised inventory systems.⁵⁷ Independent pharmacies will require individual reporting.
• Veterinary stocks: Provet NZ and veterinary practices — inventory simultaneously.
• Aged care facilities: Report on-hand stocks.

Day 7–14: Establish the National Pharmaceutical Triage Authority

PHARMAC convenes the authority, drawing on its therapeutic group managers, Medsafe regulatory staff, clinical pharmacologists from major hospitals, and senior pharmacists. The authority’s first task: confirm the triage categories (Section 2) and issue national rationing protocols.

7.2 Short-term actions (Weeks 2–12)

Implement SLEP protocols

• The Triage Authority issues guidance to all pharmacies and hospitals: medications beyond labeled expiry should not be discarded. Instead, they should be assessed under SLEP-based criteria and, for drugs with strong extension evidence, relabeled with extended use-by dates.
• Publish a national list of drugs and their evidence-based extended shelf lives, drawing on SLEP data, independent research, and Medsafe regulatory expertise. This list should be tiered: (a) drugs with strong evidence for 5+ year extension; (b) drugs with moderate evidence for 2–5 year extension; (c) drugs with limited data — use with clinical judgement; (d) drugs that should NOT be used beyond expiry (tetracyclines, degraded insulin, etc.).
• Distribute the list to every pharmacy and hospital in NZ. Print it (Doc #1, Section 5.3).

Begin dose optimisation and deprescribing

• Issue clinical guidelines for dose reduction in key categories (Section 3)
• GPs and prescribers begin systematic medication reviews for their patient panels
• Priority: convert Type 2 diabetes patients from insulin to oral agents where safe (Section 3.4)
• Priority: deprescribe PPIs, statins, and benzodiazepines where clinically appropriate
• Priority: reduce antihypertensive regimens to minimum effective doses

Cold-chain audit

• Identify all cold-chain pharmaceutical stocks nationwide
• Assess backup power at each storage location
• Consolidate cold-chain stocks into facilities with the most reliable power supply
• Establish temperature monitoring protocols — daily manual checks where electronic monitoring is not available

Patient communication

This is clinically and logistically demanding. Patients who have taken a specific medication for years will be told that their supply is being rationed, their dose may be reduced, or their medication may be switched to an alternative. For many, this is alarming and disorienting, and the communication approach must account for that — without overstating either the certainty of supply exhaustion or the reassurance that extension provides.

Communication principles (developed in coordination with Doc #2):

• Honesty: “The medicine supply is finite. We are managing it to last as long as possible.”
• Clinical reasoning: “Your dose is being reduced because the evidence shows this lower dose provides nearly the same benefit.” Not: “We’re cutting your dose because we’re running out.”
• Individual attention: Mass communication about rationing is necessary, but medication changes should be communicated individually by the patient’s GP or pharmacist where possible
• Reassurance where warranted: “Most pills last much longer than the date on the label. We’re using scientific evidence to safely extend the use of medicines that are still effective.”
• Honesty where reassurance is not warranted: For patients on drugs without substitutes (insulin for Type 1 diabetes, immunosuppressants for transplant patients), the situation must be explained honestly. False reassurance would be cruel and counterproductive (Doc #2, Doc #122)

7.3 Medium-term actions (Months 3–12)

Ongoing inventory management

• Transition from initial stocktake to ongoing inventory management — track consumption rates, update stock duration projections, identify drugs approaching extended expiry limits
• Regional stock redistribution: if one region has excess of a drug another region needs, transfer it. This requires the national database to be functioning.

Stability testing (if capacity exists)

NZ has pharmaceutical analytical laboratory capacity — at Medsafe, at universities (University of Otago School of Pharmacy, University of Auckland School of Pharmacy), and at some commercial testing laboratories.⁵⁸ If this capacity can be maintained:

• Prioritise testing of high-value drugs where SLEP data is limited
• Test representative lots of NZ’s actual stock (specific brands and formulations held in-country) under actual storage conditions
• Results feed back into the shelf-life extension list, updating it with NZ-specific data

Pharmaceutical compounding

Community and hospital pharmacies have compounding capability — the ability to prepare formulations from bulk ingredients or adapt existing products for specific patient needs. Under rationing:

• Tablet splitting and re-dosing: When dose reduction is indicated, pharmacists can split tablets or repackage into dose-appropriate units. This is practical for most solid-dose tablets but not for coated or extended-release formulations, where splitting alters the release profile.
• Extemporaneous compounding: Some formulations (oral rehydration solutions, basic topical creams, simple suspensions) can be prepared from bulk raw materials. This depends on access to pharmaceutical-grade excipients — glycerol, methylcellulose, preservatives, and the like — which are themselves imported and will deplete. The compounding window is not indefinite; it is bounded by whatever bulk excipient stocks are in the country at the time of the event.
• This is not manufacturing. Compounding is small-scale, patient-specific preparation from existing ingredients. It extends flexibility at the margins but does not create new active pharmaceutical ingredient supply. When bulk ingredients are exhausted, compounding stops.

Integration with Doc #119 (Local Production)

Doc #119 covers the longer-term challenge of domestic pharmaceutical production. The rationing framework should identify which drugs are running out fastest relative to patient need, to prioritise production development efforts. The Triage Authority provides this data to the production development team.

Rongoā Māori and pharmaceutical demand reduction

Rongoā Māori — particularly plant-based preparations with confirmed antibacterial properties (mānuka, kawakawa, kūmarahou) for wound care, mirimiri for musculoskeletal pain, and traditional respiratory and gastrointestinal remedies — can reduce pharmaceutical demand in lower-acuity categories where substitution is clinically safe. Existing Māori health provider networks and rongoā practitioners represent operational capacity for this. The Triage Authority should engage iwi health providers early to develop joint protocols identifying which pharmaceutical categories can be partially offset by rongoā alternatives, prioritising topical wound care, mild-to-moderate musculoskeletal pain, and non-acute respiratory and GI complaints.

---

8. SPECIFIC DRUG CATEGORIES — DETAILED ANALYSIS

[Phase 1–3: Drug-specific protocols are implemented from Phase 1. As stocks of individual categories are exhausted or confirmed adequate, their management transitions — some categories derationed by Phase 2–3, others (insulin, biologics) remaining under tight control throughout.]

8.1 Antibiotics

Why this matters: Antibiotics are the drugs most likely to be needed in increased quantities post-event. Without access to modern surgical facilities (some will continue; some won’t), wound infections become more common. Manual labour increases injury rates. Reduced sanitation in some settings increases infectious disease. Dental infections — normally treated by a dentist within days — become serious if untreated.

NZ antibiotic stock (estimate): Several months of normal consumption across the formulary. The most commonly prescribed antibiotics in NZ are amoxicillin/amoxicillin-clavulanate, cefalexin, doxycycline, trimethoprim, flucloxacillin, ciprofloxacin, and metronidazole.⁵⁹

Shelf-life extension: Most antibiotic tablets and capsules extend well — 5–10+ years for many. Amoxicillin capsules have demonstrated stability well beyond labeled expiry. Ciprofloxacin tablets are among the most stable drugs in the SLEP database. Exception: Amoxicillin and other antibiotic oral suspensions (liquid forms used for children) have shorter extension potential (1–3 years). Powder for reconstitution is more stable until reconstituted.

Rationing protocol:

• Antibiotics prescribed only for confirmed or high-probability bacterial infections. No prescribing for viral illnesses (a persistent peacetime problem that becomes unacceptable under rationing)
• Shorter courses where evidence supports it — the trend in infectious disease medicine toward shorter antibiotic courses (3–5 days rather than 7–14 for many infections) is evidence-based and saves supply⁶⁰
• Narrow-spectrum agents preferred (amoxicillin before amoxicillin-clavulanate; cefalexin before ciprofloxacin) to preserve broad-spectrum agents for resistant infections
• Hospital antibiotic stewardship programmes — already established in NZ — intensified

8.2 Cardiovascular drugs

Population: NZ has a large cardiovascular disease burden. Approximately 500,000–700,000 NZers take antihypertensive medications; roughly 300,000–400,000 take statins; approximately 80,000–100,000 are on anticoagulants.⁶¹⁶²

Good news: Most cardiovascular drugs are solid oral dose forms with excellent shelf-life extension potential. Amlodipine, atenolol, metoprolol, enalapril, losartan, hydrochlorothiazide, simvastatin, atorvastatin — all extend well beyond labeled expiry in SLEP and independent data.

Warfarin: The preferred anticoagulant under rationing conditions. It is cheap, available in large quantities, tablets extend well, and NZ has the laboratory infrastructure for INR monitoring. The newer direct oral anticoagulants (DOACs: dabigatran, rivaroxaban, apixaban) are clinically convenient but more expensive, less available, and have no reversal agent in NZ stock. Transition DOAC patients to warfarin where clinically feasible.

Dose optimisation opportunity: This is the category with the largest dose reduction potential. Many patients are overtreated relative to what evidence supports in a rationing context. The dose-response evidence for antihypertensives supports half-dose treatment as broadly effective for blood pressure control,⁶³ and the LDL dose-response curve for statins means halving the dose costs approximately 20% of LDL-lowering effect rather than 50%.⁶⁴ Taken across the full cardiovascular population, aggressive but clinically appropriate dose optimisation could extend the effective supply of cardiovascular medications by an estimated 25–50%, though the actual figure depends on the proportion of patients who can be safely reduced and how many can be deprescribed entirely. This estimate has no published NZ-specific basis and should be treated as a planning assumption pending actual prescribing data from the national inventory.

8.3 Psychiatric medications

Population: Approximately 500,000+ NZers take psychiatric medications (antidepressants, anxiolytics, antipsychotics, mood stabilisers).⁶⁵ The post-event mental health burden will be immense (Doc #122), creating increased demand at exactly the moment supply becomes constrained.

Critical safety issue: Abrupt withdrawal from many psychiatric medications is dangerous:

• SSRI/SNRI discontinuation syndrome: Dizziness, nausea, anxiety, insomnia, electric shock sensations. Unpleasant and distressing but not usually lethal.
• Benzodiazepine withdrawal: Can cause seizures and death. Must be tapered slowly.
• Antipsychotic withdrawal: Risk of psychotic relapse. Must be managed.
• Lithium withdrawal: Risk of manic relapse. Must be managed.
• Anticonvulsant mood stabilisers (valproate, carbamazepine): Withdrawal risks seizures. Must be tapered.

Rationing protocol:

• No abrupt discontinuation. All psychiatric medication changes are supervised tapers.
• Patients on low-priority psychiatric medications (sleep aids, mild anxiolytics) tapered first, with non-pharmacological support (Doc #122)
• Patients with severe mental illness (schizophrenia, bipolar disorder, severe depression with suicidal ideation) maintained on medication as long as stock allows — these are Category 2–3 drugs
• SSRI supply: fluoxetine (Prozac) has a very long half-life, which means it can be given at reduced frequency (every other day or every third day) with maintained effect. This effectively doubles or triples the supply.⁶⁶

8.4 Respiratory medications

Population: Approximately 500,000+ NZers have asthma; approximately 35,000–50,000 have COPD.⁶⁷ These patients depend on inhaled medications — primarily salbutamol (reliever) and inhaled corticosteroids (preventer).

Shelf-life extension for inhalers: Metered-dose inhalers (MDIs) depend on propellant (HFA) and valve integrity as well as drug stability. Extension potential is moderate — 2–5 years beyond labeled expiry in most cases, less than for tablets. Dry powder inhalers (DPIs) may have slightly better extension potential as they do not depend on propellant.

Rationing protocol:

• Prioritise preventer inhalers (inhaled corticosteroids) — reducing airway inflammation reduces the need for reliever inhalers
• Ensure asthma patients have written action plans to minimise acute exacerbations
• Oral prednisone (tablets, long shelf life) as backup for severe exacerbations
• Nebuliser solutions extend the utility of liquid salbutamol stock — nebulisers in hospitals and community settings

8.5 Pain management

The analgesic ladder under rationing:

1. Paracetamol and ibuprofen — first-line for most pain. Both are very stable, extend well (5–10+ years). NZ stocks are likely substantial.
2. Codeine and tramadol — second-line. Tablets extend well. Rationed more strictly as supply is smaller.
3. Morphine and other strong opioids — third-line, for severe pain and surgical anaesthesia. Rationed to hospital and supervised-care settings. Oral morphine tablets extend well; injectable morphine ampoules have moderate extension potential.
4. Non-pharmacological pain management — physical therapy, heat/cold, TENS (transcutaneous electrical nerve stimulation), acupuncture, psychological techniques — becomes much more important under rationing. These approaches are evidence-based and should be actively promoted.

---

9. THE SUPPLY GAP: WHEN RATIONING MEETS PRODUCTION TIMELINES

9.1 The three dimensions of pharmaceutical loss

The consequences of pharmaceutical depletion are not limited to mortality. Three distinct categories of harm must be tracked, because each imposes different costs on the recovery:

Mortality — patients who die without the drug. Insulin for Type 1 diabetes, immunosuppressants for transplant recipients, epinephrine for anaphylaxis. These are the starkest cases, but they are not the largest category of harm.

Functional incapacity — patients who survive but can no longer work, think clearly, or live independently. An epilepsy patient without anticonvulsants cannot safely operate machinery, drive, or work at heights. A patient with severe schizophrenia without antipsychotics may require constant supervision, consuming caregiving resources. A severe asthma patient without inhalers cannot sustain physical labour. These individuals are not fatality statistics, but they have been effectively removed from the recovery workforce — and in many cases they impose additional caregiving burdens on people who would otherwise be doing recovery work.

Degraded effectiveness — patients who can still function but at significantly reduced capacity. Untreated hypertension causes chronic headaches, fatigue, and reduced concentration. Untreated depression reduces motivation, decision-making quality, and interpersonal effectiveness. Untreated chronic pain slows physical work and disrupts sleep. Individually, these seem like acceptable compromises under scarcity. Aggregated across hundreds of thousands of affected people, the cumulative productivity loss is substantial — and for specific individuals whose skills are irreplaceable, the downstream effects can be severe for everyone who depends on their output.

9.2 Physical supply vs. chemical shelf life: the critical distinction

Two different constraints determine how long NZ’s pharmaceutical stocks last, and conflating them produces dangerously optimistic planning assumptions.

Physical volume — how many months of consumption the total in-country stock represents. NZ’s pharmaceutical supply chain holds approximately 3–5 months of normal consumption across all stock layers: wholesale warehouses (4–8 weeks), hospital pharmacies (0.5–1 week), community pharmacies (1–2 weeks), household stocks from NZ’s 90-day dispensing cycle (~6 weeks for chronic medications), and veterinary stocks (0.5–1 week for dual-use antibiotics).⁶⁸ This is the binding constraint for most drug categories. The exact figures are unknown until the national inventory (Action 4) is complete — but the order of magnitude is months, not years.

Chemical shelf life — how long the drugs remain chemically effective beyond their labeled expiry. For most solid-dose tablets, SLEP evidence shows 5–15+ years of retained potency (Section 4, Appendix A). This means tablets consumed within the first year of the crisis are fully effective. But shelf-life extension does not create more pills. Once the physical stock is consumed, SLEP is irrelevant.

The practical implication: under any rationing scenario, most drug categories are physically exhausted within months. SLEP matters for extending the usable window — a tablet consumed in Month 8 is still chemically effective because SLEP confirms potency years beyond labeled expiry — but it does not change the fact that there are only so many tablets. For a small number of categories with exceptionally favorable volume-to-consumption ratios (levothyroxine, phenobarbital), physical supply measured in months of pipeline stock translates to years of actual supply because the doses are tiny or the patient population is small relative to typical wholesale purchase volumes. For most drugs, the crisis is measured in months.

9.3 Supply duration under three rationing scenarios

The following estimates are based on total in-country pharmaceutical stock — aggregated across wholesale warehouses, hospital pharmacies, community pharmacies, household stocks (NZ’s 90-day dispensing cycle means chronic-medication households hold approximately six weeks of supply), and veterinary stocks where applicable — adjusted by consumption reduction factors achievable under each rationing protocol. Domestic production timelines are from Doc #119 and represent realistic, not best-case, estimates. All estimates carry significant uncertainty and must be refined through the immediate national inventory (Action 4).

Three scenarios are compared:

Scenario A — No rationing. Uncontrolled consumption and hoarding. Panic buying depletes pharmacy-level stocks within weeks; no national redistribution; cold-chain failures destroy insulin and biologics; high-value drugs prescribed for low-value indications at normal rates.

Scenario B — Moderate rationing. 30-day dispensing limits, secured warehouses, national inventory and redistribution, cold-chain management, basic therapeutic switching. No systematic deprescribing or age-weighted allocation.

Scenario C — Aggressive rationing with age-weighted allocation. All of the above, plus systematic dose optimization and deprescribing, aggressive Type 2 diabetes insulin-to-oral conversion with lifestyle management, deprescribing of marginal-benefit medications in elderly patients, recovery-value-weighted allocation, strict antibiotic stewardship, and age-weighted priority when supply of a life-sustaining drug is insufficient for all patients who need it. Where age-weighted allocation applies, supply durations differ substantially between younger and older patients — these are shown separately.

Drug category	Population affected	Scenario A	Scenario B	Scenario C: under 50	Scenario C: over 50/65	Domestic production (Doc #119)
Insulin	20–25K Type 1; 40–60K Type 2 on insulin	2–3 months	3–5 months	2.5–3.5 years for under-30 (shelf-life limited†); ~1.8 years if extended to under-50	0–3 months (deprioritised)	Animal: Year 3–5 crude, Year 5–10 clinical
Immunosuppressants	3–4K transplant	2–3 months	3–4 months	3–5 months	3–5 months	Not achievable. [D]
Anticonvulsants	50–65K epilepsy	3–5 months	4–7 months	5–9 months	5–9 months	Phenobarbital: Year 7–10
Antibiotics (all classes)	Entire pop. (episodic)	2–4 months	4–7 months	8–16 months (priority access)	2–6 months (deprioritised)	Crude penicillin: Year 3–7
Cardiovascular	500–700K antihypertensives; 300–400K statins	3–5 months	5–8 months	10–18 months (deprescribing frees supply)	3–6 months (deprescribed where marginal)	Aspirin: Year 5–10
Psychiatric	500K+ on medications	3–5 months	4–7 months	6–10 months	6–10 months	Not achievable. [D]
Respiratory (inhalers)	500K+ asthma/COPD	2–4 months	3–5 months	4–7 months	4–7 months	Not achievable. [D]
Analgesics	Entire pop. (episodic + chronic)	3–5 months	5–8 months	7–14 months	7–14 months	Morphine: Year 3–5. Aspirin: Year 5–10
Thyroid (levothyroxine)	200K+	4–6 months	6–10 months	10–20+ months	10–20+ months	Not achievable. [D]
Contraceptives	Reproductive-age pop.	3–5 months	5–8 months	7–12 months (IUDs in situ: 5–10 years)	n/a	Not achievable. [D]

†Insulin shelf-life constraint: The volume of insulin available under age-weighted allocation (320,000 patient-months allocated to ~10,000 under-30 patients = ~32 months per patient) exceeds the usable shelf life of the stock. Insulin degrades under refrigeration; labeled shelf life is 2–3 years from manufacture, with an estimated 6–12 months of SLEP extension under ideal cold storage (Section 4.3). The usable supply window is approximately 2.5–3.5 years — bounded by insulin degradation, not by consumption volume. This is tight but potentially sufficient to bridge to crude domestic production if cold-chain integrity is maintained and production begins by Year 3. See Section 9.4 for detailed analysis.

Note on age-weighted columns: For drug categories where age-weighted allocation applies (insulin, antibiotics, cardiovascular), the “under 50” and “over 50/65” columns show the effective supply duration for each group. For categories where age-weighting does not meaningfully apply (immunosuppressants — no scope for reduction; anticonvulsants, psychiatric, respiratory — age is less relevant to allocation; thyroid, analgesics — broadly distributed), both columns show the same duration. The under-50 durations are longer because supply freed from deprescribed elderly patients is redirected to younger patients.

Note on uncertainty: These estimates are derived from general pharmaceutical supply chain data, not from actual NZ stock counts. The immediate national inventory (Action 4) is the single most important action in this document — until it is complete, every number in this table is an informed estimate, not a fact. Actual stock levels for specific drugs may be significantly higher or lower than these ranges.

9.4 What happens under each scenario

Scenario A (no rationing) — first 12 months:

Pharmaceutical stocks are effectively exhausted within 2–5 months across all major categories. Hoarding concentrates remaining supply in some households while others get nothing. Cold-chain failures destroy insulin and biologics in locations where backup power fails. The consequences in the first year:

• ~20,000–25,000 deaths from insulin exhaustion (Type 1 diabetes), including all ~5,000 children with Type 1. Diabetic ketoacidosis develops within days to weeks of insulin cessation. This is the single largest pharmaceutical mortality category.
• ~3,000–4,000 deaths from organ rejection as immunosuppressant supply is exhausted.
• Thousands of additional deaths from untreated bacterial infections (wound sepsis, pneumonia, urinary tract infections), uncontrolled seizures (status epilepticus), cardiovascular events (stroke, myocardial infarction), and suicide (untreated psychiatric illness). Over the multi-year antibiotic gap (3–5 years to crude penicillin production), infection deaths accumulate to an estimated 10,000–35,000.
• Tens of thousands of people rendered functionally incapacitated: uncontrolled epilepsy (cannot safely work), unmanaged severe mental illness (psychotic episodes, catatonia), uncontrolled asthma (cannot sustain physical labour), severe chronic pain.
• Hundreds of thousands experiencing degraded capacity: untreated hypertension, depression, anxiety, moderate chronic pain — each individually tolerable, collectively a substantial drag on recovery productivity.

Conservative aggregate estimate: 35,000–56,000 pharmaceutical-attributable excess deaths over Years 1–5, including antibiotic-gap mortality. Functional incapacity affecting an additional 50,000–100,000 people. Degraded effectiveness affecting 300,000–500,000.

Scenario B (moderate rationing) — first 12 months:

Dispensing limits prevent hoarding. Redistribution ensures geographic equity. Cold-chain management preserves insulin and biologics. Supply extends by 1–4 months for most categories. But without systematic deprescribing, total consumption remains close to peacetime rates, and the same mortality categories arrive within months:

• Insulin still exhausted by Month 5–6 at latest. ~20,000–25,000 Type 1 deaths — including all ~5,000 children — delayed but not prevented.
• Immunosuppressant, anticonvulsant, and psychiatric medication stocks follow within months.
• Antibiotic gap mortality accumulates over years, as in Scenario A, though somewhat reduced by better initial stewardship.
• Moderate rationing buys time for the system to organize, but does not change the fundamental arithmetic: there are not enough pills for everyone at anything close to current prescribing rates.

Conservative aggregate estimate: 29,000–50,000 excess deaths over Years 1–5 — slightly lower than Scenario A due to better distribution and cold-chain management, but the binding volume constraint is unchanged. All Type 1 children still die.

Scenario C (aggressive rationing with age-weighted allocation) — first 24 months:

Aggressive rationing achieves meaningful supply extension through three mechanisms: deprescribing patients for whom medication provides marginal benefit, dose optimization for patients who continue, and reallocation of freed supply to highest-value uses. It also introduces a fourth mechanism that fundamentally changes one outcome: age-weighted allocation within drug categories, particularly insulin.

The largest single supply gain is Type 2 diabetes insulin-to-oral conversion: if 50–60% of Type 2 insulin users can be managed on oral agents and lifestyle modification, total insulin consumption drops by roughly 40%. This converts approximately 300,000–320,000 patient-months of insulin supply from the pre-rationing total.

• Insulin — the age-weighted allocation insight: Distributed equally across all ~22,000 Type 1 patients, 320,000 patient-months of supply lasts approximately 14 months. Most patients still die years before domestic production. But NZ has approximately 5,000 Type 1 diabetics under age 18 and approximately 10,000 under age 30.⁶⁹ If insulin is allocated preferentially by age, the volume-based supply durations are:

  • Children only (under 18): 320,000 / 5,000 = ~64 months ≈ 5 years by volume — but shelf-life limited to ~2.5–3.5 years (see below).
  • Under 30: 320,000 / 10,000 = ~32 months ≈ 2.7 years.
  • Under 50: 320,000 / 15,000 = ~21 months ≈ 1.8 years.

  However, insulin shelf life — not volume — becomes the binding constraint under children-only allocation. Insulin is a protein that degrades over time even under ideal cold storage (2–8°C). Labeled shelf life is 2–3 years from manufacture; SLEP-type extension under ideal conditions adds an estimated 6–12 months at most (Section 4.3). NZ’s in-country stock was not all manufactured on Day 0 — the wholesale pipeline turns over continuously, so stock at the point of supply severance has a distribution of remaining shelf life, from nearly new (recently imported) to near-expiry. A reasonable estimate of the average remaining labeled shelf life is 12–18 months, with SLEP extension adding 6–12 months — yielding approximately 18–30 months of usable shelf life for the average vial.⁷⁰

  The practical effect: under children-only allocation, the volume of insulin (64 patient-months per child) exceeds the shelf life. Not all of it can be used before it degrades. The usable supply window is approximately 2.5–3.5 years — bounded by the shelf life of the last usable vials, not by consumption. This is tight but potentially sufficient to bridge to the earliest crude animal insulin production (Year 3–5 per Doc #119), provided three conditions are met: (1) cold-chain integrity is maintained at high reliability for the full period (any failure destroys irreplaceable stock); (2) the oldest stock is consumed first (FEFO — first expiry, first out) to maximise the usable window; and (3) domestic animal insulin production achieves at least crude output by Year 3. If production takes the full 5 years, a gap of 0.5–1.5 years opens even under children-only allocation. The bridge is plausible but not assured.

  Under the under-30 allocation (320,000 / 10,000 = 32 months ≈ 2.7 years), the volume and shelf-life constraints roughly coincide — supply duration and usable life are in the same range. This is probably the most realistic target: it maximises the number of young patients bridged while staying within the insulin’s usable life.

  The cost: approximately 7,000–12,000 adult Type 1 patients (primarily those over 50) lose access to insulin within months and die from diabetic ketoacidosis within days to weeks. This is the hardest choice in this document. It is also the most consequential — the difference between “all 22,000 Type 1 patients die” and “5,000–10,000 of the youngest survive to domestic production.”

• Immunosuppressants: Supply extends to 3–5 months. Essentially no scope for consumption reduction — withdrawal means graft rejection. ~3,000–4,000 transplant deaths over 1–3 years. Unchanged from other scenarios.

• Antibiotics — age-weighted allocation: Supply extends to 6–12 months through strict stewardship (no prescribing for viral infections, narrow-spectrum first, reserve broad-spectrum). Age-weighted allocation applies the same logic as insulin: patients over 65 account for a disproportionate share of antibiotic consumption (pneumonia, urinary tract infections, post-surgical infections, skin and soft-tissue infections are all more common with age). Restricting antibiotic use primarily to patients under 50 could extend the effective supply window by an additional 2–4 months for younger patients, because elderly patients consume an estimated 30–40% of total antibiotic volume.⁷¹ During those additional months, hundreds to thousands of younger patients survive treatable infections they would otherwise have died from. After stock exhaustion, everyone faces pre-antibiotic-era conditions until crude penicillin production begins (Year 3–7). Estimated infection deaths during the gap period: 2,300–7,300 per year,⁷² accumulating to 10,000–35,000 over 3–5 years — but under age-weighted allocation, a larger share of those deaths falls among elderly patients during the rationing period, and a smaller share among children and young adults. This makes antibiotics the second-largest mortality category after insulin over a multi-year horizon, and the second category where age-weighted allocation produces a substantial person-years benefit.

• Cardiovascular: Supply extends to 7–14 months. Combined with post-event lifestyle changes (lower caloric intake, more physical activity, dietary shift away from processed food), many patients’ cardiovascular risk decreases independently of medication. Estimated 500–2,000 additional cardiovascular deaths per year as stocks thin — substantially lower than without medication, but a real and sustained increase.

• Psychiatric: Supply extends to 6–10 months. Careful tapering (not abrupt cessation) reduces acute withdrawal crises. Long-half-life drugs (fluoxetine) stretched further through extended dosing intervals. Suicide risk and severe psychiatric incapacity increase as stocks deplete. No domestic replacement available.

Conservative aggregate estimate over Year 1–5: 30,000–53,000 excess deaths — but with a fundamentally different composition from Scenarios A and B. Insulin deaths drop from 20,000–25,000 to 7,000–12,000 because age-weighted allocation saves 5,000–10,000 of the youngest patients. Antibiotic-gap deaths, properly accounted over the multi-year gap period, add 10,000–35,000 — a category that rationing cannot prevent but can delay. The rate of pharmaceutical-attributable death slows in Year 3–5 as crude domestic production (penicillin, morphine, aspirin, ether) begins to fill selected gaps.

9.5 Age-stratified mortality under each scenario

The aggregate death estimates in Section 9.4 obscure the most important feature of aggressive rationing: where the deaths fall. The following table breaks pharmaceutical-attributable mortality into age cohorts under each scenario, with person-years of life lost calculated from NZ age-specific life expectancy.⁷³

Table: Pharmaceutical-attributable excess deaths by age cohort — Year 1–5 estimates

Age cohort	NZ pop. (approx.)	Scenario A (no rationing)	Scenario B (moderate)	Scenario C (aggressive + age-weighted)
Children (0–17)	1.1M	2,500–4,000 (Type 1: ~5,000 paediatric patients; infection deaths)	2,000–3,500	100–400 (most Type 1 children bridged to domestic insulin; antibiotic priority reduces infection deaths)
Young adults (18–49)	1.9M	10,000–15,000 (Type 1; infections; psychiatric)	8,000–13,000	3,000–7,000 (many Type 1 bridged; antibiotic priority extends coverage; gap-period deaths still accumulate)
Older working-age (50–64)	0.7M	8,000–12,000 (Type 1; cardiovascular; infections)	7,000–11,000	10,000–16,000 (insulin redirected from this cohort; cardiovascular deprescribing; reduced antibiotic access)
Elderly (65+)	0.8M	15,000–25,000 (cardiovascular; infections; deprescribing-equivalent natural attrition)	12,000–22,000	17,000–30,000 (deprescribing increases cardiovascular/other mortality; antibiotic deprioritisation increases infection deaths)
Total	5.2M	35,000–56,000	29,000–50,000	30,000–53,000

The aggregate death counts are similar across scenarios — but the person-years of life saved are not.

Metric	Scenario A	Scenario B	Scenario C
Total excess deaths (Year 1–5)	35,000–56,000	29,000–50,000	30,000–53,000
Person-years of life lost	~1,500,000–2,500,000	~1,200,000–2,200,000	~600,000–1,200,000
Ratio to Scenario A	1.0x	0.8–0.9x	0.4–0.5x

The person-years divergence is dramatic because age-weighted allocation — applied to both insulin and antibiotics — concentrates mortality among elderly patients (average remaining life expectancy ~10–15 years) while saving children and young adults (average remaining life expectancy ~55–70 years). Every child with Type 1 diabetes who survives to domestic insulin production represents ~65 person-years of life saved. Every child who survives a treatable infection because antibiotics were reserved for younger patients represents a similar gain. Every elderly patient who dies earlier from deprescribing or untreated infection represents ~5–15 person-years lost. The ratio is approximately 5:1 to 10:1 per individual — and when multiplied across the affected population, Scenario C saves roughly 2–2.5x as many person-years of life as Scenario A, despite similar total death counts.

What this means concretely for children: Under Scenarios A and B, approximately 5,000 children with Type 1 diabetes die — all of them — because insulin is consumed at adult rates and runs out before any domestic production begins. Hundreds more die from untreated infections because antibiotics are consumed without age priority. Under Scenario C with age-weighted allocation, most of those children can potentially survive to domestic animal insulin production — but this outcome depends on maintaining cold-chain integrity for the full 2.5–3.5 year usable insulin window and achieving at least crude domestic animal insulin production by Year 3 (Section 9.4). If cold-chain failures destroy stock or domestic production takes the full 5 years projected in Doc #119, a gap opens and some children are lost. Antibiotic prioritisation reduces paediatric infection deaths during the rationing window. The cost of this outcome is that 7,000–12,000 adult Type 1 patients, predominantly over 50, die within months instead of within a year, and elderly patients with treatable infections are deprioritised for antibiotic treatment. Both sets of numbers are real. But one represents children who could have lived full lives, and the other represents adults whose remaining supply — even under the most optimistic extension — would not have bridged the gap to domestic production anyway.

9.6 The mechanism of age-weighted allocation

Scenario C requires confronting a tradeoff that Scenarios A and B avoid by default.

Aggressive deprescribing redirects medication from patients with shorter expected benefit duration — primarily elderly patients with comorbidities — to patients with longer expected benefit duration — primarily younger adults. Concretely: an 82-year-old on a statin for primary cardiovascular prevention and a moderate-dose antihypertensive is deprescribed; the freed medication extends supply for a 45-year-old with severe hypertension. The elderly patient’s cardiovascular risk increases. Some will have strokes or heart attacks sooner than they would have under Scenario B.

But the insulin and antibiotic age-weighting are the far harder decisions. These are not deprescribing marginal-benefit medications — they are withdrawing life-sustaining treatment from older patients to extend supply for younger ones.

For insulin: a 55-year-old Type 1 diabetic who has managed the disease for decades will be told that their insulin allocation is being redirected to a 12-year-old — and that without insulin, they will die within weeks. This is not an abstraction. It is a decision that will be made about specific people.

For antibiotics: an 80-year-old presenting with pneumonia will not receive antibiotic treatment, so that the same course of antibiotics remains available for a child who develops a wound infection next month. The elderly patient may die from a condition that would have been treatable. The difference from insulin is that antibiotic allocation is episodic — decided case by case as infections present — rather than a single categorical decision. This makes it harder to implement consistently, and harder for clinicians who must decide at the bedside not to treat a patient they could save.

NZ has approximately 800,000 people aged 65+, of whom roughly 500,000–600,000 are on at least one chronic medication.⁷⁴ Patients over 65 consume an estimated 30–40% of total antibiotic volume.⁷⁵ Aggressive deprescribing of marginal-benefit medications in this population could free 15–25% of total cardiovascular and related drug stocks. Age-weighted antibiotic allocation could extend effective supply for younger patients by 2–4 months. Age-weighted insulin allocation could potentially save most of NZ’s ~5,000 Type 1 children — if cold-chain integrity is maintained and domestic production begins by Year 3.

This is not a hidden feature of the rationing programme. It is the mechanism by which aggressive rationing achieves its results. If the programme is not willing to deprescribe elderly patients and age-weight both insulin and antibiotic allocation, it cannot achieve Scenario C outcomes — it achieves something between Scenario B and C, with correspondingly worse person-year results and thousands of avoidable child and young-adult deaths. The choice is real: distribute medication equally regardless of age (more person-years lost, all Type 1 children die, younger infection patients die alongside elderly ones), or allocate based on expected benefit duration (fewer person-years lost, most Type 1 children survive, more young adults survive treatable infections, more elderly deaths). Section 10 addresses the ethical framework for making this choice transparently.

9.7 Conclusions

Five conclusions emerge from this analysis:

First, physical volume — not shelf life — is the binding constraint. For most drug categories, in-country stock is measured in months of consumption. SLEP keeps those pills effective, but it does not create more of them. Planning assumptions based on “5–15 years of shelf-life extension” are dangerously misleading unless they are grounded in actual stock volumes.

Second, aggregate death counts are misleading — person-years of life saved is the relevant metric. Scenarios A and C produce similar total death counts (35,000–56,000 vs 30,000–53,000 over five years), which makes aggressive rationing appear to offer only modest benefit. But the person-years analysis reveals that Scenario C saves roughly 2–2.5x as many life-years, because it concentrates mortality among elderly patients with shorter remaining life expectancy while saving children and young adults with decades ahead of them.

Third, age-weighted allocation can potentially save most of NZ’s ~5,000 Type 1 children and hundreds more from untreated infections — but the insulin bridge is tight. This is the single most consequential finding in this analysis. For insulin: under equal distribution, all ~22,000 Type 1 patients die within a year; under age-weighted allocation, children and young adults can potentially bridge to domestic animal insulin production — but insulin shelf life (2.5–3.5 years of usable supply under ideal cold storage) is the binding constraint, not volume. The bridge to domestic production (Year 3–5) is plausible but depends on cold-chain reliability and early production success. For antibiotics: age-weighted allocation extends the supply window for younger patients by 2–4 months, during which hundreds to thousands of children and young adults survive treatable infections. The cost — accelerated deaths among older patients — is real, but those patients were not going to bridge the gap to domestic production regardless.

Fourth, antibiotic mortality accumulates over years and is larger than single-year estimates suggest. During the 3–5 year gap between stock exhaustion and crude penicillin production, NZ faces pre-antibiotic-era infection mortality rates: an estimated 2,300–7,300 deaths per year, accumulating to 10,000–35,000. This makes antibiotics the second-largest pharmaceutical mortality category over the full gap period, after insulin. Age-weighted antibiotic allocation does not eliminate this gap — it shifts who dies during the rationing period so that more of the finite antibiotic supply protects younger patients.

Fifth, the aggregate impact of degraded effectiveness is larger than the aggregate mortality. The hundreds of thousands of people functioning at reduced capacity — from untreated hypertension, depression, chronic pain, anxiety, epilepsy with breakthrough seizures, uncontrolled asthma — represent a diffuse but enormous drag on the recovery. This is a reason to take the degraded-effectiveness category seriously in allocation decisions and to apply recovery-value weighting (Section 10.3) where a modest pharmaceutical investment in one individual produces disproportionate benefit for others.

---

10. ETHICAL FRAMEWORK

10.1 Principles

Pharmaceutical rationing forces explicit choices that peacetime abundance obscures. The ethical framework must be stated openly:

1. Maximise total health benefit from finite supply. The goal is the greatest aggregate health outcome from the medicines available. This is a utilitarian principle and is the primary allocation criterion. “Health benefit” includes not only direct clinical benefit to the patient but also downstream effects — the functional capacity that medication preserves, and what that capacity means for the people who depend on it (see Principle 6).

2. Equity of access within triage categories. Within a given triage category, access should be based on clinical need, not wealth, location, ethnicity, or social status. The same drug goes to the same clinical need regardless of who the patient is. However, equity does not mean ignoring outcome-relevant differences. When two patients have the same clinical need but the expected duration of benefit differs substantially — because of age, comorbidities, or life expectancy — Principle 1 (maximise total health benefit) takes precedence. This tension is addressed explicitly in Section 10.2.

3. Transparency. Allocation criteria are published. Decisions are documented. The public knows the rules. This is non-negotiable — secret rationing criteria would destroy trust.

4. Proportionality. Rationing is proportionate to actual scarcity. As stocks of specific drugs are confirmed to be adequate (through inventory and shelf-life extension), rationing of those drugs is relaxed. Unnecessary restriction is as harmful as insufficient restriction, because it erodes compliance.

5. Human dignity. Even when a medication cannot be provided, the patient deserves honest communication, palliative alternatives where they exist, and respect. “We cannot provide this drug” is not the same as “we have given up on you.”

6. Recovery-value weighting. When a person’s functional capacity directly affects the survival or welfare of others, the downstream consequences of their incapacity are a legitimate factor in allocation decisions. This is not a separate principle — it is an honest application of Principle 1. But it requires stating explicitly because standard medical triage does not normally consider it, and because failing to consider it under sustained scarcity produces worse aggregate outcomes. Section 10.3 addresses this in detail.

10.2 The hardest decisions

End-of-supply scenarios. Some patients will run out of life-sustaining medications before alternatives become available. The gap analysis in Section 9.3 identifies the specific categories:

• Type 1 diabetes patients — insulin stocks last an estimated 5–10 months under aggressive rationing if distributed equally across all Type 1 patients (Section 9.3). Under age-weighted allocation (Section 9.4), most of NZ’s ~5,000 Type 1 children can potentially be bridged to domestic animal insulin production (Year 3–5) — but the bridge is constrained by insulin shelf life (2.5–3.5 years under ideal cold storage), not volume, and depends on cold-chain reliability and early production success. Approximately 7,000–12,000 adult patients — predominantly over 50 — face supply exhaustion within months. For those patients, the constraint is terminal.
• Transplant recipients — immunosuppressant stocks last 3–5 months under aggressive rationing; no domestic production is achievable. Approximately 3,000–4,000 patients face organ rejection and likely death as stocks deplete.
• Patients on specific biologics with no alternative (some autoimmune conditions, some cancers) — stocks last months; no domestic replacement.

There is no technical solution to this. It is a resource constraint. The ethical obligation is:

• Maximum extension of supply through everything in this document — SLEP, dose optimisation, storage, rationing
• Honest communication — early, not at the point of depletion. Patients deserve time to prepare, emotionally and practically.
• Palliative care — when curative or maintenance treatment is no longer possible, comfort care continues. NZ’s hospice and palliative care infrastructure (Hospice NZ, Te Omanga Hospice, and regional hospice services) should be expanded and supported.⁷⁶
• Research and production development — every month of extended supply is a month for Doc #119’s domestic production programme to make progress. Buying time is the strategy.

Age, polypharmacy, and the allocation tension. Principles 1 and 2 conflict most sharply in one population: elderly patients on multiple medications. NZ has a significant population of older adults taking 5 or more medications (polypharmacy).[^11 in Doc #4] Many of these medications manage chronic conditions — hypertension, Type 2 diabetes, osteoporosis, cholesterol — where the benefit accrues over years to decades. When total supply is finite, continuing a full medication regimen for a patient with a life expectancy of 3–5 years consumes supply that could extend treatment for a younger patient with a life expectancy of 30–50 years.

It is a quantitative observation: the same medication quantity produces more total life-years of benefit when allocated to patients with longer expected benefit duration. The recovery goal — stabilise society, reduce suffering, maximise functional population over the recovery period — requires confronting this arithmetic honestly.

Practical resolution:

1. Aggressive deprescribing for elderly patients on multiple medications. Many medications prescribed to elderly patients under peacetime conditions provide marginal benefit — statins for primary prevention in over-80s, bisphosphonates for mild osteoporosis, mild antihypertensives where blood pressure is only modestly elevated. These should be the first medications withdrawn, not because the patients do not matter but because the clinical benefit is small relative to the supply consumed. Clinical pharmacists and GPs should review all patients aged 75+ for deprescribing opportunities within the first month.
2. Tapering, not abrupt withdrawal. Even when a decision is made to discontinue a medication for an elderly patient, withdrawal should be managed through gradual dose reduction — not abrupt cessation. Abrupt withdrawal of beta-blockers, SSRIs, benzodiazepines, and opioids is medically dangerous at any age. Tapering schedules should be published as part of the rationing guidelines.
3. Transparent criteria. The criteria for prioritisation must be published. If expected benefit duration is a factor in allocation (and it should be), this must be stated openly — not implemented quietly through clinical “discretion.” Secret age-based rationing would be far more socially destructive than transparent, justified age-based rationing. The population can accept hard choices if they understand the reasoning; they cannot accept choices made behind closed doors.
4. Continued care. Deprescribing is not abandonment. Patients whose medications are reduced or discontinued continue to receive monitoring, non-pharmacological management, and palliative care where appropriate. The message is: “We are prioritising this medication for patients who will benefit for longer, and we are managing your transition carefully” — not “we have given up on you.”
5. Societal acceptance. These decisions will be difficult for the public. Open communication about the reasoning — grounded in the shared goal of maximum survival and recovery — is essential. People are more likely to accept age-considered allocation when the rationale is honestly explained and when they can see that the elderly continue to receive care and dignity, even when specific medications are redirected.

10.3 Recovery-value weighting

Standard medical triage allocates based on individual clinical benefit: who is most likely to survive, who will benefit most from treatment. In a mass casualty event lasting hours or days, this is the right framework — the social role of the patient is irrelevant when you are deciding who gets the last unit of blood in an emergency department.

A multi-year pharmaceutical rationing scenario is fundamentally different. When scarcity lasts years and one person’s functional capacity materially affects the survival or welfare of hundreds or thousands of others, the individual-clinical-benefit framework produces worse aggregate outcomes than one that accounts for downstream effects.

The argument is a direct extension of Principle 1. If the goal is to maximise total health benefit from finite supply, then the health benefit of keeping a surgeon functional includes the operations that surgeon performs. The health benefit of keeping the one person who can operate the Glenbrook steel mill’s electric arc furnace (Doc #89) on their anticonvulsants includes the steel output that keeps other industrial processes running. The health benefit of keeping a midwife’s depression treated includes the maternal and neonatal outcomes she influences. In each case, the pharmaceutical cost is small — one person’s medication — and the downstream benefit is large.

This is not “important people deserve better treatment.” It is the same utilitarian calculus the document already endorses, applied honestly to include effects beyond the individual patient. The distinction matters:

• Not a general social-status criterion. A wealthy person does not receive priority because of wealth. A popular person does not receive priority because of popularity. Recovery-value weighting applies only when there is a specific, documented link between a person’s functional capacity and the welfare of others who depend on it.
• Not a permanent entitlement. Priority access is tied to a specific functional role during the recovery period, not to personal status. When the role is filled by others or the scarcity in question resolves, the weighting no longer applies.
• Applies across all three dimensions of pharmaceutical loss. Recovery-value weighting is easiest to see in the degraded-effectiveness category — the mechanic whose untreated arthritis halves their output, the pharmacist whose unmanaged anxiety reduces their clinical judgement — where a modest pharmaceutical investment produces outsized returns in functional capacity. But it applies to life-sustaining drugs too. When supply of a life-sustaining drug is insufficient for all patients who need it, and one patient’s survival materially affects the survival of many others, the utilitarian calculus that governs the rest of this framework applies to that decision as well. This is uncomfortable but consistent: the alternative is to allocate life-sustaining drugs without regard to downstream effects, which produces a worse aggregate outcome by the framework’s own criteria.

Implementation:

1. The Triage Authority maintains a recovery-value register in coordination with the workforce allocation system (Doc #145). Individuals whose functional roles have been identified as critical are flagged for priority allocation within their triage category.
2. Decisions are documented and published. Every recovery-value allocation is recorded with the reasoning: what role the person fills, why the role is critical, why the pharmaceutical investment produces disproportionate benefit. No secret lists.
3. The register is reviewed quarterly. As roles are filled by others, as training programmes produce replacement skills, or as drug supply concerns resolve, individuals are removed from priority status.
4. Scale is limited. Recovery-value weighting should apply to hundreds of individuals, not tens of thousands. If the register grows beyond a small fraction of the affected population, it has become a general entitlement rather than a targeted allocation tool, and the Triage Authority should tighten eligibility criteria.
5. Public communication is essential. The reasoning must be explained openly: “We are prioritising this person’s arthritis medication because they are the only person who can maintain the transformer that keeps the hospital’s cold chain running, and that cold chain preserves the insulin supply for 20,000 people.” When the chain of benefit is made visible, most people will accept the logic. When it is hidden, it looks like favouritism.

10.4 Governance and accountability

The National Pharmaceutical Triage Authority must be:

• Clinically led. Politicians set the mandate (“maximise health outcomes from finite supply”), clinicians make the allocation decisions.
• Publicly accountable — regular reporting on stock levels, allocation decisions, and rationale. Minutes of meetings published.
• Subject to review — decisions can be challenged through the appeals process. External review by an ethics committee (drawing on NZ’s existing Health and Disability Ethics Committees framework).⁷⁷
• Clinically representative of NZ’s population health profile — must include clinicians experienced with Māori and Pacific populations, who have substantially different disease prevalence patterns (e.g., 2–3× diabetes prevalence in Māori, higher cardiovascular disease in Pacific populations), as well as rural health and disability expertise. These are not representational appointments — they are functional necessities because differential disease prevalence across populations is a direct pharmacological allocation variable. A triage authority that lacks this clinical knowledge will misallocate supply.

---

11. CROSS-REFERENCES AND DEPENDENCIES

Document	Relationship to this document
Doc #1 — National Emergency Stockpile Strategy	Pharmaceutical stocks are Category A (wholesale) and Category B (controlled distribution). This document provides the detailed pharmaceutical-specific implementation
Doc #2 — Public Communication	Patient and public communication about medication rationing, supply constraints, and end-of-supply scenarios
Doc #3 — Food Rationing	Nutritional management affects pharmaceutical requirements. Dietary changes may reduce need for some medications (diabetes, cardiovascular). Supplement rationing managed through pharmaceutical system
Doc #156 — Census	Skills and asset census must include pharmaceutical inventory, medical workforce, and pharmaceutical production expertise
Doc #65 — Hydro Maintenance	Grid reliability determines cold-chain reliability, which determines insulin and biologics shelf life
Doc #74 — Pastoral Farming	Veterinary pharmaceutical requirements for livestock health
Doc #91 — Machine Shop Operations	Equipment maintenance for any future pharmaceutical production
Doc #119 — Local Pharmaceutical Production	Domestic production of selected drugs — the long-term supply solution for drugs that cannot be extended indefinitely
Doc #122 — Mental Health	Psychiatric medication rationing must be coordinated with mental health support framework. Medication withdrawal without psychosocial support is dangerous
Doc #129 — AI Inference Centre	AI-assisted clinical decision support for triage, deprescribing, therapeutic switching, and diagnostic assistance when specialists are unavailable

---

CRITICAL UNCERTAINTIES

Uncertainty	Impact if wrong	Resolution method
Actual in-country pharmaceutical stock levels	Over-estimated stock means earlier depletion than planned; under-estimated stock means unnecessarily strict rationing	National inventory (Section 7.1) — this is the single highest-priority information-gathering task
Applicability of SLEP data to NZ-held stock	SLEP tested US military stocks stored under US military conditions. NZ stocks are different brands, stored under different conditions. Extension may be greater or less than SLEP suggests	NZ-specific stability testing (Section 7.3). Until then, SLEP data is the best available guide and is conservative in most cases
Insulin supply duration and shelf life	Under age-weighted allocation, volume is sufficient to bridge children and young adults to domestic production — but shelf life is the binding constraint. Usable window estimated at 2.5–3.5 years under ideal cold storage. If actual shelf life is shorter (due to prior storage conditions or batch variability), the bridge to domestic production fails and children die	Immediate insulin inventory with manufacturing dates (highest-priority unknown). Prioritise consumption of oldest stock first (FEFO). Accelerate domestic animal insulin production timeline (Doc #119)
Cold-chain reliability over 2.5–3.5 years	Under age-weighted insulin allocation, cold-chain integrity for the full usable window is critical — any failure destroys irreplaceable stock and shortens the bridge to domestic production. Every vial lost to cold-chain failure is a vial a child cannot use	Backup power at all insulin storage sites, consolidation into fewer monitored locations, continuous temperature monitoring (Section 5.4). This is not routine infrastructure maintenance — it is a prerequisite for saving ~5,000 children’s lives
Patient compliance with dose reduction	Patients may resist medication changes, obtain drugs through informal channels, or stop taking medications entirely	Clinical communication, trust, and a functioning appeals process. GPs and pharmacists are the key interface
Type 2 diabetes response to lifestyle changes	The assumption that many Type 2 patients can reduce or eliminate insulin/oral agents with lifestyle change is plausible but untested at population scale under these conditions	Monitor outcomes closely. This is an assumption, not a fact. Have contingency for higher-than-expected insulin demand
Veterinary stock usability for humans	Some veterinary formulations may not be suitable for human use due to excipients, dose forms, or contamination risk	Expert review board (Section 6.2). Product-by-product assessment required
Nuclear winter effect on pharmaceutical storage	Cooler temperatures generally favour drug stability, but humidity changes are uncertain. Flooding or structural damage to warehouses could destroy stock	Protect warehouse infrastructure. Monitor storage conditions. Multiple storage locations
Public acceptance of pharmaceutical rationing	If perceived as unfair, the system collapses into hoarding, black markets, and non-compliance	Transparency, procedural justice, visible equity — same principles as food rationing (Doc #3, Section 9)
Antibiotic resistance patterns post-event	With reduced access to culture and sensitivity testing, empirical antibiotic prescribing may increase resistance	Maintain lab capacity where possible. Stewardship programmes. Narrow-spectrum first

---

APPENDIX A: SUMMARY OF SHELF-LIFE EXTENSION EVIDENCE BY DRUG CLASS

This table summarises the best available evidence. “Extension” refers to the period beyond labeled expiry during which the drug retains acceptable potency (generally >90% of labeled content) under recommended storage conditions. These are conservative estimates based on published SLEP and independent data.

Drug / Class	Formulation	Estimated extension beyond expiry	Evidence strength	Key reference
Paracetamol	Tablets	5–10+ years	Strong	SLEP, Cantrell 201278
Ibuprofen	Tablets	5–10+ years	Strong	SLEP
Aspirin	Tablets	5–10+ years	Strong	Cantrell 201279
Amoxicillin	Capsules/tablets	2–5 years	Moderate–strong	SLEP
Amoxicillin	Oral suspension	1–2 years (reconstituted: days)	Moderate	Limited data
Ciprofloxacin	Tablets	10+ years	Strong	SLEP80
Doxycycline	Tablets/capsules	1–3 years (conservative due to safety concern)	Moderate	Precautionary81
Metformin	Tablets	5–10+ years	Moderate–strong	SLEP, independent
Atenolol	Tablets	5–10+ years	Strong	SLEP
Amlodipine	Tablets	5–10+ years	Strong	SLEP
Enalapril	Tablets	5–10+ years	Strong	SLEP
Hydrochlorothiazide	Tablets	5–10+ years	Strong	SLEP
Simvastatin/Atorvastatin	Tablets	3–7 years	Moderate	Limited SLEP data
Warfarin	Tablets	3–7 years	Moderate	SLEP
Levothyroxine	Tablets	5–10+ years	Moderate–strong	SLEP
Prednisone	Tablets	5+ years	Moderate–strong	SLEP
Fluoxetine	Capsules	3–7 years	Moderate	Limited data
Morphine	Tablets	3–7 years	Moderate	SLEP
Codeine	Tablets	5–10+ years	Strong	Cantrell 201282
Salbutamol	MDI inhaler	2–5 years	Moderate	Propellant/valve dependent
Insulin (all types)	Injectable solution	0.5–1 year (refrigerated)	Limited	Cold-chain critical83
Nitroglycerin	Sublingual tablets	0.5–1 year	Weak–moderate	Volatile compound84
Diazepam	Tablets	5+ years	Moderate	SLEP
Phenobarbital	Tablets	5–10+ years	Strong	Cantrell 201285

---

APPENDIX B: NZ PHARMACEUTICAL SUPPLY CHAIN KEY ENTITIES

Entity	Role	Relevance to rationing
PHARMAC	National pharmaceutical funding and procurement agency	Centralised purchasing data; therapeutic switching expertise; leads Triage Authority
Medsafe	Medicines regulator (Ministry of Health)	Regulatory authority for shelf-life extension guidance; emergency dispensing rules
EBOS Group	Parent company of ProPharma and CDC Pharmaceuticals	Dominant pharmaceutical wholesale distributor — controls majority of in-country pipeline stock86
ProPharma	Primary pharmaceutical wholesaler (EBOS subsidiary)	Auckland and Christchurch warehouses — the physical location of most wholesale stock
CDC Pharmaceuticals	Secondary wholesaler (EBOS subsidiary)	Additional wholesale capacity
Green Cross Health	Pharmacy chain (Unichem, Life Pharmacy brands)	~280+ pharmacies — significant community-level stock and dispensing capacity87
Chemist Warehouse NZ	Pharmacy/retail chain	Growing presence — additional community stock and high-volume OTC sales
Douglas Pharmaceuticals	NZ-based generic manufacturer (Auckland)	Limited domestic manufacturing capacity; relies on imported APIs88
AFT Pharmaceuticals	NZ-based pharmaceutical company (Auckland)	Some NZ manufacturing; primarily imported products
Te Whatu Ora / Health NZ	Public health system	Hospital pharmacies, prescribing infrastructure, clinical governance
University of Otago School of Pharmacy	Academic/research	Pharmaceutical analytical capability for stability testing89
University of Auckland School of Pharmacy	Academic/research	Additional analytical and compounding expertise
Provet NZ (EBOS subsidiary)	Veterinary pharmaceutical distributor	Veterinary stock integration90
PGG Wrightson / Farmlands	Agricultural supply retailers	Veterinary and agricultural pharmaceutical stocks

---

---

1. NZ Health Survey (Ministry of Health / Manatū Hauora). https://www.health.govt.nz/nz-health-statistics/national-... — The NZ Health Survey collects data on long-term medication use. The figure of approximately 1.2 million NZ adults on at least one long-term medication is approximate; exact figures depend on the survey year and definition of “long-term.” Figure requires verification against the most recent NZ Health Survey release. The NZ adult population is approximately 4 million, so this represents approximately 30% of adults — consistent with high-income country norms for medicated chronic disease prevalence.↩︎

2. Lyon RC, Taylor JS, Porter DA, et al. “Stability Profiles of Drug Products Extended beyond Labeled Expiration Dates.” Journal of Pharmaceutical Sciences 95(7):1549–1560, 2006. https://pubmed.ncbi.nlm.nih.gov/16894557/ — The foundational SLEP publication. Tested 122 drugs (3,005 lots) from military stockpiles between 1986 and 2005. Found 88% of lots were extended, with a mean extension of 5.5 years beyond labeled expiry. This is the strongest published evidence on pharmaceutical shelf-life extension.↩︎

3. Pharmacy Council of New Zealand workforce data. https://www.pharmacycouncil.org.nz/ — NZ has approximately 4,000+ registered pharmacists working across approximately 1,000 community pharmacies and hospital pharmacy departments. These numbers are approximate and change annually.↩︎

4. NZ Ministry of Health pharmaceutical supply monitoring during COVID-19, 2020–2021. Documented shortages of paracetamol, ibuprofen, and other essential medicines during the early pandemic period in NZ and across Australia–New Zealand supply chains. The pattern — public stockpiling rapidly depleting retail and pharmacy-level supply, creating shortages for patients with genuine clinical need — is well documented in pandemic-era pharmaceutical supply literature.↩︎

5. EBOS Group Annual Reports and corporate disclosures. https://www.ebosgroup.com/ — EBOS Group is an ASX/NZX-listed company that owns ProPharma (NZ’s dominant pharmaceutical wholesaler) and CDC Pharmaceuticals. Together these entities handle the majority of NZ’s pharmaceutical wholesale distribution, with primary warehouses in Auckland and Christchurch. EBOS also owns Provet NZ (veterinary distribution). Stock levels are commercially sensitive and not publicly reported.↩︎

6. EBOS Group Annual Reports and corporate disclosures. https://www.ebosgroup.com/ — EBOS Group is an ASX/NZX-listed company that owns ProPharma (NZ’s dominant pharmaceutical wholesaler) and CDC Pharmaceuticals. Together these entities handle the majority of NZ’s pharmaceutical wholesale distribution, with primary warehouses in Auckland and Christchurch. EBOS also owns Provet NZ (veterinary distribution). Stock levels are commercially sensitive and not publicly reported.↩︎

7. Pharmacy Council of New Zealand workforce data. https://www.pharmacycouncil.org.nz/ — NZ has approximately 4,000+ registered pharmacists working across approximately 1,000 community pharmacies and hospital pharmacy departments. These numbers are approximate and change annually.↩︎

8. PHARMAC Annual Reports. https://www.pharmac.govt.nz/ — PHARMAC manages the Combined Pharmaceutical Budget, approximately NZ$1.2–1.4 billion per year (figure fluctuates annually), funding approximately 2,000 chemical entities in the national formulary. PHARMAC’s role, unique internationally, gives NZ centralised pharmaceutical procurement data that most countries lack.↩︎

9. Medsafe — New Zealand Medicines and Medical Devices Safety Authority. https://www.medsafe.govt.nz/ — A business unit of the Ministry of Health / Manatū Hauora. Responsible for regulating medicines and medical devices in NZ, including approval, labelling, and post-market surveillance.↩︎

10. PHARMAC Annual Reports. https://www.pharmac.govt.nz/ — PHARMAC manages the Combined Pharmaceutical Budget, approximately NZ$1.2–1.4 billion per year (figure fluctuates annually), funding approximately 2,000 chemical entities in the national formulary. PHARMAC’s role, unique internationally, gives NZ centralised pharmaceutical procurement data that most countries lack.↩︎

11. Stats NZ trade statistics and MBIE analysis of pharmaceutical imports. NZ pharmaceutical imports are approximately NZ$2.5–3 billion per year by value. The exact figure varies annually and depends on classification methodology. NZ’s pharmaceutical trade deficit is substantial — NZ imports far more pharmaceuticals than it exports.↩︎

12. Douglas Pharmaceuticals. https://www.douglas.co.nz/ — NZ’s largest domestic pharmaceutical manufacturer, based in Auckland. Manufactures generic finished dose forms (tablets, capsules, liquids) but relies on imported active pharmaceutical ingredients (APIs) sourced primarily from India and China. Also: AFT Pharmaceuticals. https://www.aftpharm.com/ — NZ-headquartered pharmaceutical company with some domestic manufacturing capacity; also API-import dependent. Note: Multichem is a NZ pharmacy chain (retail dispensing), not a pharmaceutical manufacturer, and has been removed from this list. No NZ company manufactures APIs domestically for any commonly prescribed drug class.↩︎

13. PHARMAC Annual Reports. https://www.pharmac.govt.nz/ — PHARMAC manages the Combined Pharmaceutical Budget, approximately NZ$1.2–1.4 billion per year (figure fluctuates annually), funding approximately 2,000 chemical entities in the national formulary. PHARMAC’s role, unique internationally, gives NZ centralised pharmaceutical procurement data that most countries lack.↩︎

14. EBOS Group Annual Reports and corporate disclosures. https://www.ebosgroup.com/ — EBOS Group is an ASX/NZX-listed company that owns ProPharma (NZ’s dominant pharmaceutical wholesaler) and CDC Pharmaceuticals. Together these entities handle the majority of NZ’s pharmaceutical wholesale distribution, with primary warehouses in Auckland and Christchurch. EBOS also owns Provet NZ (veterinary distribution). Stock levels are commercially sensitive and not publicly reported.↩︎

15. EBOS Group Annual Reports and corporate disclosures. https://www.ebosgroup.com/ — EBOS Group is an ASX/NZX-listed company that owns ProPharma (NZ’s dominant pharmaceutical wholesaler) and CDC Pharmaceuticals. Together these entities handle the majority of NZ’s pharmaceutical wholesale distribution, with primary warehouses in Auckland and Christchurch. EBOS also owns Provet NZ (veterinary distribution). Stock levels are commercially sensitive and not publicly reported.↩︎

16. NZ Health Survey (Ministry of Health / Manatū Hauora). https://www.health.govt.nz/nz-health-statistics/national-... — The NZ Health Survey collects data on long-term medication use. The figure of approximately 1.2 million NZ adults on at least one long-term medication is approximate; exact figures depend on the survey year and definition of “long-term.” Figure requires verification against the most recent NZ Health Survey release. The NZ adult population is approximately 4 million, so this represents approximately 30% of adults — consistent with high-income country norms for medicated chronic disease prevalence.↩︎

17. Diabetes New Zealand and Ministry of Health data. https://www.diabetes.org.nz/ — Approximately 270,000–300,000 NZers have diagnosed diabetes (combined Type 1 and Type 2). Type 1 prevalence is approximately 20,000–25,000 (roughly 10% of total). Type 2 prevalence approximately 250,000+. These figures include only diagnosed cases; undiagnosed Type 2 adds an estimated 50,000–100,000. Maori and Pacific populations have 2–3x higher prevalence rates.↩︎

18. Organ Donation New Zealand / Australia and New Zealand Organ Donation Registry. NZ performs approximately 150–200 organ transplants per year. The cumulative population of active transplant recipients requiring immunosuppression is estimated at 3,000–4,000.↩︎

19. NZ anticoagulant prescribing data from PHARMAC and Best Practice Advocacy Centre (bpac). https://bpac.org.nz/ — Estimates of 80,000–100,000 NZers on anticoagulant therapy are approximate, based on atrial fibrillation prevalence, venous thromboembolism treatment, and valve replacement populations.↩︎

20. Epilepsy New Zealand. https://www.epilepsy.org.nz/ — Epilepsy prevalence in NZ is approximately 1–1.3% of the population, or roughly 50,000–65,000 people, consistent with international prevalence data.↩︎

21. Levothyroxine is one of the most commonly prescribed medications in NZ. PHARMAC data indicates very high prescribing volumes. The estimate of 200,000+ patients is consistent with international hypothyroidism prevalence (3–5% of the population, predominantly women).↩︎

22. Cantrell FL, et al. “Stability of Active Ingredients in Long-Expired Prescription Medications.” Archives of Internal Medicine 172(21):1685–1687, 2012. Also: Cantrell FL, et al. “Epinephrine Concentrations in EpiPens After the Expiration Date.” Annals of Internal Medicine 166(12):918–919, 2017. Found EpiPens retained 84% of labeled epinephrine content at 4 years past expiry.↩︎

23. Asthma and Respiratory Foundation NZ. https://www.asthmafoundation.org.nz/ — NZ has one of the highest asthma prevalence rates in the world. Approximately 1 in 7 children and 1 in 8 adults have asthma. COPD prevalence estimates from the BOLD study and NZ-specific data suggest 35,000–50,000 with moderate-to-severe COPD.↩︎

24. NZ Health Survey data (Ministry of Health). https://www.health.govt.nz/nz-health-statistics/national-... — Medicated hypertension prevalence is approximately 12–14% of the adult population. Combined with population data, this yields approximately 500,000–700,000 NZers on antihypertensive medications.↩︎

25. Law MR, et al. “Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.” BMJ 338:b1665, 2009. Blood pressure reduction is more important than which drug is used. Lower doses of multiple agents are as effective as full doses of fewer agents, with fewer side effects.↩︎

26. Cholesterol Treatment Trialists’ Collaboration. “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.” Lancet 376(9753):1670–1681, 2010. LDL reduction follows a log-linear dose-response curve — halving the dose reduces LDL reduction by approximately 20%, not 50%.↩︎

27. Reimer C, et al. “Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.” Gastroenterology 137(1):80–87, 2009. Also: NZ bpac guidance on PPI deprescribing. https://bpac.org.nz/ — Many patients on long-term PPIs can be safely withdrawn with a tapering protocol.↩︎

28. Pottie K, et al. “Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline.” Canadian Family Physician 64(5):339–351, 2018. Supervised tapering of long-term benzodiazepines is safe and often improves patient outcomes.↩︎

29. Scott IA, et al. “Reducing inappropriate polypharmacy: the process of deprescribing.” JAMA Internal Medicine 175(5):827–834, 2015. Also: Page AT, et al. “The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.” British Journal of Clinical Pharmacology 82(3):583–623, 2016.↩︎

30. Stats NZ population demographics and Ministry of Health prescribing data. NZ has a growing elderly population; polypharmacy (5+ medications) is common in older age groups. Specific aggregate polypharmacy statistics for NZ are limited in public sources.↩︎

31. Scott IA, et al. “Reducing inappropriate polypharmacy: the process of deprescribing.” JAMA Internal Medicine 175(5):827–834, 2015. Also: Page AT, et al. “The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.” British Journal of Clinical Pharmacology 82(3):583–623, 2016.↩︎

32. Diabetes New Zealand and Ministry of Health data. https://www.diabetes.org.nz/ — Approximately 270,000–300,000 NZers have diagnosed diabetes (combined Type 1 and Type 2). Type 1 prevalence is approximately 20,000–25,000 (roughly 10% of total). Type 2 prevalence approximately 250,000+. These figures include only diagnosed cases; undiagnosed Type 2 adds an estimated 50,000–100,000. Maori and Pacific populations have 2–3x higher prevalence rates.↩︎

33. Diabetes New Zealand and Ministry of Health data. https://www.diabetes.org.nz/ — Approximately 270,000–300,000 NZers have diagnosed diabetes (combined Type 1 and Type 2). Type 1 prevalence is approximately 20,000–25,000 (roughly 10% of total). Type 2 prevalence approximately 250,000+. These figures include only diagnosed cases; undiagnosed Type 2 adds an estimated 50,000–100,000. Maori and Pacific populations have 2–3x higher prevalence rates.↩︎

34. Diabetes New Zealand and Ministry of Health data. https://www.diabetes.org.nz/ — Approximately 270,000–300,000 NZers have diagnosed diabetes (combined Type 1 and Type 2). Type 1 prevalence is approximately 20,000–25,000 (roughly 10% of total). Type 2 prevalence approximately 250,000+. These figures include only diagnosed cases; undiagnosed Type 2 adds an estimated 50,000–100,000. Maori and Pacific populations have 2–3x higher prevalence rates.↩︎

35. Ministry of Health. “Tatau Kahukura: Maori Health Chart Book.” https://www.health.govt.nz/ — Maori diabetes prevalence is approximately 2–3 times that of NZ European populations. Pacific peoples have similarly elevated rates. This creates an equity dimension to insulin rationing that must be explicitly addressed.↩︎

36. Taylor R. “Calorie restriction and reversal of Type 2 diabetes.” Expert Review of Endocrinology & Metabolism 11(6):521–528, 2016. Also: Lean MEJ, et al. “Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.” Lancet 391(10120):541–551, 2018. Weight loss and caloric restriction can achieve remission of Type 2 diabetes in a significant proportion of patients.↩︎

37. Feinman RD, et al. “Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base.” Nutrition 31(1):1–13, 2015. Low-carbohydrate diets reduce insulin requirements substantially in both Type 1 and Type 2 diabetes.↩︎

38. Lyon RC, Taylor JS, Porter DA, et al. “Stability Profiles of Drug Products Extended beyond Labeled Expiration Dates.” Journal of Pharmaceutical Sciences 95(7):1549–1560, 2006. https://pubmed.ncbi.nlm.nih.gov/16894557/ — The foundational SLEP publication. Tested 122 drugs (3,005 lots) from military stockpiles between 1986 and 2005. Found 88% of lots were extended, with a mean extension of 5.5 years beyond labeled expiry. This is the strongest published evidence on pharmaceutical shelf-life extension.↩︎

39. Lyon RC, Taylor JS, Porter DA, et al. “Stability Profiles of Drug Products Extended beyond Labeled Expiration Dates.” Journal of Pharmaceutical Sciences 95(7):1549–1560, 2006. https://pubmed.ncbi.nlm.nih.gov/16894557/ — The foundational SLEP publication. Tested 122 drugs (3,005 lots) from military stockpiles between 1986 and 2005. Found 88% of lots were extended, with a mean extension of 5.5 years beyond labeled expiry. This is the strongest published evidence on pharmaceutical shelf-life extension.↩︎

40. Subsequent SLEP programme data reported in various US DoD and FDA publications. Also: Khan SR, et al. “United States Food and Drug Administration and Department of Defense Shelf-Life Extension Program of Pharmaceutical Products: Progress and Promise.” Journal of Pharmaceutical Sciences 103(5):1331–1336, 2014. Reports cumulative SLEP results showing continued extension of hundreds of drugs well beyond labeled expiry.↩︎

41. Cohen LP. “Many Medicines Are Potent Years Past Expiration Dates.” Wall Street Journal, March 28, 2000. Reported on SLEP data and independent testing showing widespread stability beyond expiry.↩︎

42. Subsequent SLEP programme data reported in various US DoD and FDA publications. Also: Khan SR, et al. “United States Food and Drug Administration and Department of Defense Shelf-Life Extension Program of Pharmaceutical Products: Progress and Promise.” Journal of Pharmaceutical Sciences 103(5):1331–1336, 2014. Reports cumulative SLEP results showing continued extension of hundreds of drugs well beyond labeled expiry.↩︎

43. The “Fanconi syndrome from degraded tetracycline” case reports date from the 1960s and involved formulations no longer used. Modern tetracycline formulations may be safer, but the precautionary principle applies: Frimpter GW, et al. “Reversible ‘Fanconi syndrome’ caused by degraded tetracycline.” JAMA 184(2):111–113, 1963. More recent analysis suggests the risk may be lower than traditionally stated, but data is limited.↩︎

44. Insulin stability data from manufacturer product information and Vimalavathini R, Gitanjali B. “Effect of temperature on the potency & pharmacological action of insulin.” Indian Journal of Medical Research 130(2):166–169, 2009. Insulin potency degrades significantly at elevated temperatures and gradually even under refrigeration. Extension beyond labeled expiry is limited and variable.↩︎

45. Nitroglycerin sublingual tablet stability is limited by the drug’s volatility. It sublimes from tablets over time, particularly when exposed to heat or when bottles are repeatedly opened. Manufacturer data and USP standards apply.↩︎

46. Lyon RC, Taylor JS, Porter DA, et al. “Stability Profiles of Drug Products Extended beyond Labeled Expiration Dates.” Journal of Pharmaceutical Sciences 95(7):1549–1560, 2006. https://pubmed.ncbi.nlm.nih.gov/16894557/ — The foundational SLEP publication. Tested 122 drugs (3,005 lots) from military stockpiles between 1986 and 2005. Found 88% of lots were extended, with a mean extension of 5.5 years beyond labeled expiry. This is the strongest published evidence on pharmaceutical shelf-life extension.↩︎

47. Biologics stability: These are large protein molecules that are inherently less stable than small-molecule drugs. Cold-chain requirements and limited shelf life are fundamental properties of the molecular class, not conservative labelling. Extension potential is limited. See also: Hawe A, et al. “Forced Degradation of Therapeutic Proteins.” Journal of Pharmaceutical Sciences 101(3):895–913, 2012.↩︎

48. Cantrell FL, et al. “Stability of Active Ingredients in Long-Expired Prescription Medications.” Archives of Internal Medicine 172(21):1685–1687, 2012. Also: Cantrell FL, et al. “Epinephrine Concentrations in EpiPens After the Expiration Date.” Annals of Internal Medicine 166(12):918–919, 2017. Found EpiPens retained 84% of labeled epinephrine content at 4 years past expiry.↩︎

49. Cantrell FL, et al. “Stability of Active Ingredients in Long-Expired Prescription Medications.” Archives of Internal Medicine 172(21):1685–1687, 2012. Tested 8 medications (14 active ingredients) found in a retail pharmacy, 28–40 years past labeled expiry. Twelve of 14 active ingredients were present at >90% of labeled content. This is the most dramatic independent confirmation of pharmaceutical stability beyond expiry in the literature.↩︎

50. Cohen LP. “Many Medicines Are Potent Years Past Expiration Dates.” Wall Street Journal, March 28, 2000. Reported on SLEP data and independent testing showing widespread stability beyond expiry.↩︎

51. Manufacturers set expiry dates based on the minimum period for which they can guarantee stability under defined storage conditions, per ICH (International Council for Harmonisation) guidelines. Stability testing is typically conducted for 2–3 years under accelerated and real-time conditions. Manufacturers have no commercial incentive to demonstrate longer stability, and strong legal incentive to be conservative.↩︎

52. Arrhenius equation applied to pharmaceutical stability: the rate of chemical degradation approximately doubles for each 10°C increase in temperature. This is a well-established principle in pharmaceutical science. See: Waterman KC, Adami RC. “Accelerated aging: prediction of chemical stability of pharmaceuticals.” International Journal of Pharmaceutics 293(1–2):101–125, 2005.↩︎

53. NIWA Climate Atlas of New Zealand. https://niwa.co.nz/climate — NZ mean annual temperatures range from approximately 10°C in southern South Island to 16°C in Northland. Most of the population-dense regions (Auckland, Wellington, Christchurch) have mean temperatures of 12–16°C.↩︎

54. Coupe J, et al. “Nuclear Niño response observed in simulations of nuclear war scenarios.” Communications Earth & Environment 2:18, 2021. Also: Robock A, et al. “Nuclear winter revisited with a modern climate model and current nuclear arsenals: Still catastrophic consequences.” Journal of Geophysical Research: Atmospheres 112(D13), 2007. Southern Hemisphere mid-latitudes experience reduced but real cooling following a large nuclear exchange; the magnitude depends on the size of the exchange, soot injection, and atmospheric dynamics. NZ-specific temperature projections under nuclear winter conditions have not been published with precision; figures in this document are consistent with published global climate model outputs for the Southern Hemisphere mid-latitudes but should be treated as indicative rather than authoritative.↩︎

55. Many veterinary antibiotics, anti-inflammatories, and anaesthetics use the same active pharmaceutical ingredients as human formulations, manufactured to Good Manufacturing Practice (GMP) standards. The distinction between “human” and “veterinary” drugs is primarily regulatory, not chemical. See: WHO Collaborating Centre for Drug Statistics Methodology — many ATC codes have identical veterinary equivalents.↩︎

56. Provet NZ (EBOS Group subsidiary). https://www.provet.co.nz/ — NZ’s primary veterinary pharmaceutical and supplies distributor. Supplies approximately 600+ veterinary practices and agricultural retailers nationwide.↩︎

57. Green Cross Health Annual Reports. https://www.greencrosshealth.co.nz/ — Operates approximately 280+ pharmacies under the Unichem, Life Pharmacy, and other brands across NZ. Centralised purchasing and inventory systems provide aggregated stock data. Chemist Warehouse has been expanding its NZ presence with large-format discount pharmacies in major centres.↩︎

58. University of Otago School of Pharmacy. https://www.otago.ac.nz/pharmacy — Has pharmaceutical analytical laboratory facilities including HPLC, mass spectrometry, and dissolution testing capability suitable for pharmaceutical stability assessment. University of Auckland School of Pharmacy has similar capabilities. Medsafe maintains or contracts analytical testing capacity for regulatory purposes.↩︎

59. NZ antibiotic prescribing data from bpac NZ and PHARMAC reports. https://bpac.org.nz/ — Amoxicillin and amoxicillin-clavulanate are the most commonly prescribed antibiotics in NZ, followed by cefalexin, doxycycline, trimethoprim, and flucloxacillin. NZ’s antibiotic prescribing rates are moderate by international standards.↩︎

60. Spellberg B. “The New Antibiotic Mantra — ‘Shorter Is Better.’” JAMA Internal Medicine 176(9):1254–1255, 2016. Accumulating evidence supports shorter antibiotic courses (3–7 days rather than 10–14 days) for many common infections, with equivalent outcomes and reduced resistance pressure.↩︎

61. NZ anticoagulant prescribing data from PHARMAC and Best Practice Advocacy Centre (bpac). https://bpac.org.nz/ — Estimates of 80,000–100,000 NZers on anticoagulant therapy are approximate, based on atrial fibrillation prevalence, venous thromboembolism treatment, and valve replacement populations.↩︎

62. NZ Health Survey data (Ministry of Health). https://www.health.govt.nz/nz-health-statistics/national-... — Medicated hypertension prevalence is approximately 12–14% of the adult population. Combined with population data, this yields approximately 500,000–700,000 NZers on antihypertensive medications.↩︎

63. Law MR, et al. “Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.” BMJ 338:b1665, 2009. Blood pressure reduction is more important than which drug is used. Lower doses of multiple agents are as effective as full doses of fewer agents, with fewer side effects.↩︎

64. Cholesterol Treatment Trialists’ Collaboration. “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.” Lancet 376(9753):1670–1681, 2010. LDL reduction follows a log-linear dose-response curve — halving the dose reduces LDL reduction by approximately 20%, not 50%.↩︎

65. NZ Health Survey data on mental health medication use. Antidepressant prescribing in NZ has increased substantially over the past two decades. PHARMAC data shows high volumes of SSRI/SNRI prescriptions. The estimate of 500,000+ NZers on psychiatric medications is approximate, combining antidepressant, anxiolytic, antipsychotic, and mood stabiliser use.↩︎

66. Fluoxetine has an active metabolite (norfluoxetine) with a half-life of 4–16 days, making it uniquely suited to intermittent dosing. This is established pharmacology — intermittent fluoxetine dosing (e.g., every other day or weekly for some patients) is used in clinical practice for managing SSRI discontinuation and for supply-constrained settings.↩︎

67. Asthma and Respiratory Foundation NZ. https://www.asthmafoundation.org.nz/ — NZ has one of the highest asthma prevalence rates in the world. Approximately 1 in 7 children and 1 in 8 adults have asthma. COPD prevalence estimates from the BOLD study and NZ-specific data suggest 35,000–50,000 with moderate-to-severe COPD.↩︎

68. EBOS Group Annual Reports and corporate disclosures. https://www.ebosgroup.com/ — EBOS Group is an ASX/NZX-listed company that owns ProPharma (NZ’s dominant pharmaceutical wholesaler) and CDC Pharmaceuticals. Together these entities handle the majority of NZ’s pharmaceutical wholesale distribution, with primary warehouses in Auckland and Christchurch. EBOS also owns Provet NZ (veterinary distribution). Stock levels are commercially sensitive and not publicly reported.↩︎

69. Diabetes New Zealand and Ministry of Health data. Type 1 diabetes prevalence by age in NZ is not disaggregated in publicly available sources with precision. The estimate of ~5,000 paediatric Type 1 patients (under 18) is derived from NZ’s total Type 1 prevalence (~20,000–25,000) and international age-distribution data showing approximately 20–25% of Type 1 patients are under 18 (onset peaks in childhood). The under-30 estimate (~10,000) applies international incidence and prevalence curves to NZ’s population structure. These figures are estimates requiring verification against the NZ Diabetes Register (if available) or DHB clinical data.↩︎

70. Insulin shelf-life distribution at point of supply severance: NZ’s pharmaceutical wholesale pipeline turns over continuously — EBOS/ProPharma import insulin on a regular schedule to maintain buffer stock. At any given time, in-country insulin stock is a mix of recently imported product (close to full labeled shelf life remaining) and older stock closer to expiry. The estimate of 12–18 months average remaining labeled shelf life assumes a roughly uniform distribution of manufacturing dates across recent import cycles, which is a simplification — actual distribution depends on import frequency, lot sizes, and demand patterns. SLEP extension of 6–12 months for insulin is less certain than for solid-dose medications because insulin is a protein subject to aggregation and fibrillation over time even under ideal storage. Vimalavathini R, Gitanjali B. “Effect of temperature on the potency & pharmacological action of insulin.” Indian Journal of Medical Research 130(2):166–169, 2009. The combined estimate of 2.5–3.5 years of usable supply is approximate and should be refined through immediate inventory with attention to manufacturing dates and lot-specific stability data.↩︎

71. Elderly antibiotic consumption: NZ-specific age-stratified antibiotic prescribing data is not disaggregated in publicly available PHARMAC reports with sufficient detail for precise estimates. The 30–40% estimate for patients over 65 is derived from international data: Blix HS, et al. “The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals.” European Journal of Clinical Pharmacology 60:651–658, 2004. Also: Costelloe C, et al. “Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients.” BMJ 340:c2096, 2010. Elderly patients have higher rates of pneumonia, urinary tract infection, skin and soft-tissue infection, and post-surgical infection — all major antibiotic-consuming conditions. NZ bpac prescribing data confirms that antibiotic prescribing rates per capita are substantially higher in over-65 populations than in younger cohorts.↩︎

72. Pre-antibiotic-era mortality from bacterial infections: Armstrong GL, Conn LA, Pinner RW. “Trends in Infectious Disease Mortality in the United States During the 20th Century.” JAMA 281(1):61–66, 1999. Pre-antibiotic mortality rates from pneumonia, sepsis, wound infections, puerperal fever, and tuberculosis in developed countries ranged from 150–500 per 100,000 per year. Applied to NZ’s population of 5.2 million, with adjustment for modern sanitation, surgical technique, and diagnostic capability (which reduce but do not eliminate pre-antibiotic infection mortality), the estimate of 2,300–7,300 infection deaths per year during the antibiotic gap represents a range from optimistic (modern hygiene and wound care substantially reduce susceptible infections) to pessimistic (post-event conditions increase infection exposure through manual labour, reduced nutrition, and crowded housing). The figure accumulates over the 3–5 year gap between stock exhaustion and crude penicillin production.↩︎

73. Stats NZ life tables (period life tables by age and sex). NZ life expectancy at birth is approximately 80 years (male) and 83 years (female). Remaining life expectancy by age cohort: age 10 ≈ 70–73 years; age 30 ≈ 51–54 years; age 50 ≈ 32–35 years; age 65 ≈ 19–22 years; age 75 ≈ 12–14 years. Person-years calculations in Section 9.5 use these NZ-specific figures, not global averages. Under nuclear winter conditions, actual life expectancy may be somewhat lower than peacetime tables, but the relative differences between age cohorts are preserved.↩︎

74. NZ Health Survey (Ministry of Health / Manatū Hauora). https://www.health.govt.nz/nz-health-statistics/national-... — The NZ Health Survey collects data on long-term medication use. The figure of approximately 1.2 million NZ adults on at least one long-term medication is approximate; exact figures depend on the survey year and definition of “long-term.” Figure requires verification against the most recent NZ Health Survey release. The NZ adult population is approximately 4 million, so this represents approximately 30% of adults — consistent with high-income country norms for medicated chronic disease prevalence.↩︎

75. Elderly antibiotic consumption: NZ-specific age-stratified antibiotic prescribing data is not disaggregated in publicly available PHARMAC reports with sufficient detail for precise estimates. The 30–40% estimate for patients over 65 is derived from international data: Blix HS, et al. “The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals.” European Journal of Clinical Pharmacology 60:651–658, 2004. Also: Costelloe C, et al. “Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients.” BMJ 340:c2096, 2010. Elderly patients have higher rates of pneumonia, urinary tract infection, skin and soft-tissue infection, and post-surgical infection — all major antibiotic-consuming conditions. NZ bpac prescribing data confirms that antibiotic prescribing rates per capita are substantially higher in over-65 populations than in younger cohorts.↩︎

76. Hospice New Zealand. https://www.hospice.org.nz/ — NZ has approximately 32 hospice services providing palliative care nationally. Under rationing conditions with foreseeable end-of-supply for some life-sustaining medications, the demand for palliative care will increase substantially.↩︎

77. Health and Disability Ethics Committees (HDEC). https://ethics.health.govt.nz/ — NZ’s established framework for ethical review of health research and, by extension, health policy decisions. The ethical governance framework for pharmaceutical rationing should draw on this existing institutional capacity.↩︎

78. Cantrell FL, et al. “Stability of Active Ingredients in Long-Expired Prescription Medications.” Archives of Internal Medicine 172(21):1685–1687, 2012. Tested 8 medications (14 active ingredients) found in a retail pharmacy, 28–40 years past labeled expiry. Twelve of 14 active ingredients were present at >90% of labeled content. This is the most dramatic independent confirmation of pharmaceutical stability beyond expiry in the literature.↩︎

79. Cantrell FL, et al. “Stability of Active Ingredients in Long-Expired Prescription Medications.” Archives of Internal Medicine 172(21):1685–1687, 2012. Tested 8 medications (14 active ingredients) found in a retail pharmacy, 28–40 years past labeled expiry. Twelve of 14 active ingredients were present at >90% of labeled content. This is the most dramatic independent confirmation of pharmaceutical stability beyond expiry in the literature.↩︎

80. Subsequent SLEP programme data reported in various US DoD and FDA publications. Also: Khan SR, et al. “United States Food and Drug Administration and Department of Defense Shelf-Life Extension Program of Pharmaceutical Products: Progress and Promise.” Journal of Pharmaceutical Sciences 103(5):1331–1336, 2014. Reports cumulative SLEP results showing continued extension of hundreds of drugs well beyond labeled expiry.↩︎

81. The “Fanconi syndrome from degraded tetracycline” case reports date from the 1960s and involved formulations no longer used. Modern tetracycline formulations may be safer, but the precautionary principle applies: Frimpter GW, et al. “Reversible ‘Fanconi syndrome’ caused by degraded tetracycline.” JAMA 184(2):111–113, 1963. More recent analysis suggests the risk may be lower than traditionally stated, but data is limited.↩︎

82. Cantrell FL, et al. “Stability of Active Ingredients in Long-Expired Prescription Medications.” Archives of Internal Medicine 172(21):1685–1687, 2012. Tested 8 medications (14 active ingredients) found in a retail pharmacy, 28–40 years past labeled expiry. Twelve of 14 active ingredients were present at >90% of labeled content. This is the most dramatic independent confirmation of pharmaceutical stability beyond expiry in the literature.↩︎

83. Insulin stability data from manufacturer product information and Vimalavathini R, Gitanjali B. “Effect of temperature on the potency & pharmacological action of insulin.” Indian Journal of Medical Research 130(2):166–169, 2009. Insulin potency degrades significantly at elevated temperatures and gradually even under refrigeration. Extension beyond labeled expiry is limited and variable.↩︎

84. Nitroglycerin sublingual tablet stability is limited by the drug’s volatility. It sublimes from tablets over time, particularly when exposed to heat or when bottles are repeatedly opened. Manufacturer data and USP standards apply.↩︎

85. Cantrell FL, et al. “Stability of Active Ingredients in Long-Expired Prescription Medications.” Archives of Internal Medicine 172(21):1685–1687, 2012. Tested 8 medications (14 active ingredients) found in a retail pharmacy, 28–40 years past labeled expiry. Twelve of 14 active ingredients were present at >90% of labeled content. This is the most dramatic independent confirmation of pharmaceutical stability beyond expiry in the literature.↩︎

86. EBOS Group Annual Reports and corporate disclosures. https://www.ebosgroup.com/ — EBOS Group is an ASX/NZX-listed company that owns ProPharma (NZ’s dominant pharmaceutical wholesaler) and CDC Pharmaceuticals. Together these entities handle the majority of NZ’s pharmaceutical wholesale distribution, with primary warehouses in Auckland and Christchurch. EBOS also owns Provet NZ (veterinary distribution). Stock levels are commercially sensitive and not publicly reported.↩︎

87. Green Cross Health Annual Reports. https://www.greencrosshealth.co.nz/ — Operates approximately 280+ pharmacies under the Unichem, Life Pharmacy, and other brands across NZ. Centralised purchasing and inventory systems provide aggregated stock data. Chemist Warehouse has been expanding its NZ presence with large-format discount pharmacies in major centres.↩︎

88. Douglas Pharmaceuticals. https://www.douglas.co.nz/ — NZ’s largest domestic pharmaceutical manufacturer, based in Auckland. Manufactures generic finished dose forms (tablets, capsules, liquids) but relies on imported active pharmaceutical ingredients (APIs) sourced primarily from India and China. Also: AFT Pharmaceuticals. https://www.aftpharm.com/ — NZ-headquartered pharmaceutical company with some domestic manufacturing capacity; also API-import dependent. Note: Multichem is a NZ pharmacy chain (retail dispensing), not a pharmaceutical manufacturer, and has been removed from this list. No NZ company manufactures APIs domestically for any commonly prescribed drug class.↩︎

89. University of Otago School of Pharmacy. https://www.otago.ac.nz/pharmacy — Has pharmaceutical analytical laboratory facilities including HPLC, mass spectrometry, and dissolution testing capability suitable for pharmaceutical stability assessment. University of Auckland School of Pharmacy has similar capabilities. Medsafe maintains or contracts analytical testing capacity for regulatory purposes.↩︎

90. Provet NZ (EBOS Group subsidiary). https://www.provet.co.nz/ — NZ’s primary veterinary pharmaceutical and supplies distributor. Supplies approximately 600+ veterinary practices and agricultural retailers nationwide.↩︎